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I N T R O D U C T I O N . 
Higher forms of life are to be found in multi-
cellular organisms. According to their morphological 
and functional differentiation the cells of these 
organisms are grouped in organs which serve one or 
more specialized functions .For an adequate functioning 
of the organism as a whole, to make it capable of 
meeting the influences from the inner and outer world, 
there must be a high degree of co-ordination in the 
action of the various organs and cells. A great part 
of the mutual influences between the various organs 
of the body is accounted for by the nervous system. 
Many cells of this system have long offshoots, the 
nerve-fibres. Along these fibres, which may bridge 
distances of various lengths (cm to m), travel nerve 
impulses, carrying information from one part of the 
organism to another. The impulses travel along these 
fibres at a rate of about 100 m/sec., according to 
the type of the fibres. 
In addition to this quick transport of informa-
tion on the neural route along the nerve fibres, there 
is also a much slower transport which makes use of a 
humoral system. This means that substances formed in 
one organ or in certain cells are conveyed by circul-
ation or by diffusion to other organs where they may 
induce effects. The substances mentioned are called 
hormones. The neural and the hormonal system are 
responsible for the integration of the various func-
tions in different parts of the body. 
A closer study of the neural system reveals that 
the junctions between the nerve cells, the neurons and 
between the neurons and the cells of the various 
innervated organs are not contiguous. In many of these 
junctions, called synapses, there is a cleft. The gap 
is bridged by chemical substances, the neurotrans-
mitters. They are released at the side of the synaps 
where the impulse enters, the presynaptic elements, 
and move to the other side, interacting there in some 
way with the postsynaptic elements and inducing an 
impulse in the postsynaptic neurons or an effect in 
the effector cells (e.g. the contraction of a muscle). 
The neurotransmitters are often called neurohormones 
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or neurohumours. These terms, however, can better be 
kept for those neurocrine products which are produced 
in other organs them those in which they induce their 
effect. Examples are Oxytocine and Vasopressine, pro-
ducts of the hypophysis, which act on the uterus, the 
kidney, etc. 
The neurocrine products that are responsible for 
the transmission of a nerve impulse act very locally. 
For this reason it is better not to use the term 
neurohormones or neurohumours but neurotransmitters 
or neurotransmitting substances. 
As has been said, in order to transmit impulses 
the molecules of the neurotransmitter have to inter-
act in some way with the postsynaptic cell, neuron 
or effector cell. On this cell, specific receptors 
are postulated with which the molecules of the neuro-
transmitter interact. These receptors may be mole-
cules, molecule-complexes or parts of them, located 
on the synaptic cell-membrane. Practically nothing 
is known about the nature of the receptors. In many 
biological processes enzymes play an essential role. 
So it may be that in a number of cases the receptors 
are the active sites of enzymes. As far as the break-
down of the neurotransmitters is concerned, enzymes 
are definitely involved. 
C l a s s i f i c a t i o n o f t h e s y n a p -
s e s . 
The synapses can be classified according to the 
neurotransmitting substance involved. 
A c e t y l c h o l i n e . 
If acetylcholine is involved, the synapses are 
called cholinergic. Among them we can distinguish: 
a. The synapses in the central nervous system. Still 
very little information is available about these 
synapses. 
b. The ganglionic synapses. These are interneuronal 
synapses outside the central nervous system. 
c. The parasympathetic endsynapses. These are the 
synapses in the neuron-effector junctions of the 
parasympathetic part of the autonomous nervous 
system, mainly the terminals of the vagus nerve. 
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This nerve plays an important part in the regula-
tion of peristalsis in the intestinal tract and in 
the circulation, 
d. The endsynapses of the motor-nerves or the myoneur-
al junction. Here the striated muscle is the ef-
fector organ. The post-synaptic part is in this 
case called end-plate. 
A r t e r e n o l . 
Arterenol"·"), adrenaline"*") and possibly dopamine 
are involved in the transmission of impulses at var-
ious synapses, called adrenergic or arterenergic. 
Among them we can distinguish: 
a. The synapses in the central nervous system. The 
information on these synapses is very scarce. 
b. The sympathetic endsynaps. These are the synapses 
in the neuro-effector junction of the sympathetic 
part of the autonomous nervous system. It is of 
importance in the regulation of the tonus and the 
contraction in the muscle of the vascular wall and 
of the heart action, therefore in the regulation 
of the circulation. 
These compounds, especially adrenaline, have the 
character of a real hormone, as far as they are pro-
duced by the adrenal medulla. 
S e r o t o n i n e . 
This compound influences neurotransmission in the 
ganglionic synaps as well as in the synaps in the 
central nervous system (l). Whether the compound 
really acts as a neurotransmitter or mainly influen-
ces the neurotransmission by acetylcholine is still 
an open question. 
H i s t a m i n e . 
Some authors suggest t h a t t h i s compound is involved 
e s p e c i a l l y a t the percept ive endings of the sensory 
nerves (2 , 3 ) · In t h i s case , t oo , i t i s not c l e a r 
whether histamine r e a l l y ac t s as a neu ro t r ansmi t t e r . 
+) Synonyms of arterenol : norepinephrine, noradrenaline. 
Synonyms of adrenaline: epinephrine, N-methyl-arterenol. 
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C h e m i c a l v a r i a n c e 
o f t h e n e u r o t r a n s m i t t e r s . 
A number of the effects caused by stimulation of 
the parasympathetic or sympathetic nerves can also 
be obtained by intravenous injection of acetyl-
choline or arterenol. Compounds related in chemical 
structure to the neurotransmitters may also bring 
about the effects as obtained by nerve stimulation. 
The compounds acting as acetylcholine are called 
acetylcholinomimetics. As far as the effects of stim-
ulation of the parasympathetic nerves are concerned, 
they are called parasympathomimetics. Compounds that 
act as arterenol or adrenaline are called sympatho-
mimetics. As a rule the mimetics, at least the more 
active ones, are very closely related in their chemi-
cal structure to the corresponding neurotransmitter. 
The actions of the mimetics can be explained by 
the hypothesis that the molecules of these substances 
occupy the same receptors as those on which the neuro-
transmitters act and have the ability to induce an 
effect. 
From the special literature it is known that by 
modification of the chemical structure of the mimetics 
substances can be obtained which antagonize the action 
of the mimetics by competing with them for the spec-
ific receptors. They have an affinity to the same 
receptors as the mimetics but they do not have the 
ability to induce an effect. These compounds are 
therefore called competitive antagonists or lytics, 
e.g. acetylcholinolytics. 
In earlier studies it was demonstrated that a 
gradual change from mimetics to lytics as a result 
of the gradual change in the chemical structure is 
possible. 
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E x a m p l e I. 
By progressive substitution of one methyl group 
in tetramethylammonium by alkyl groups of increasing 
length, there is a gradual change from parasympatho­
mimetics to parasympatholytics via substances with a 
dualistic action, parasympathomimetic and parasympa­
tholytic simultaneously (k). 
Action on the frog rectus 
abdominis muscle 
BN+Me-j parasympathomimetic parasympatholytic 
R = Me ++ 
Et + + 
Pr +++ 
Bu +++ 
Am ++ 
Ilex + + 
Hept + + + 
Oct - +++ 
Dodec - ++++ 
E x a m p l e II. 
Introduction of alkyl groups of increasing length 
into carbamylcholine leads to a loss of the miotic 
activity and the introduction of mydriatic activity 
(5). 
Action on the 
R 
R2-
= H 
Me 
Et 
Pr 
Bu 
Am 
H 0 
-N-C-0-CH2--сн2--N+Мез 
rabbi 
miotic 
activity 
+++ 
++ 
+ 
t pupil 
mydriatic 
activity 
+++ 
+ + 
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E x a m p l e III. 
Introduction of alkyl groups of increasing length 
in dilvasène leads from parasympathomimetics to para-
sympatholytics via substances with a dualism in ac-
tion (6). 
Action on the rat jejunum 
0 — с 
ι ι 
R-c c-N+Me3 para- para-
o sympathomimetic sympatholytic 
R = Π + 
Me + + 
Et + -
Pr + + 
Bu - + 
Ilex - + 
The aim of our investigations is the study of the 
gradual change in the pharmacological properties as 
a function of the change in the chemical structure 
in series of derivatives of neurotransmitter substan­
ces, in which a gradual change from mimetic to lytic 
takes place. 
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14 
C h a p t e r 1 
T H E N E U R O T R A N S M I T T E R S 
1.1 I n t r o d u c t i o n . 
Before dealing with neurotransmitters and their 
chemical derivatives, it may be useful first of all 
to summarize the physiological,biochemical and phar­
macological data, which form the basis of the neuro­
transmitter concept as used to-day. 
1.2 A c e t y l c h o l i n e . 
The first to entertain the possibility that chem­
ical substances might be involved in the transmission 
of nerve impulses, was Dubois-Raymond (l875) (l)· He 
suggested that the transmission of the nerve impulse 
might be produced either electrically by action 
currents or chemically by stimulating substances, such 
as ammonia and lactic acid. Dixon (1906) (2) described 
the effects of the injection of muscarine, a substance 
isolated from a mushroom, the Amanita muscaria, as 
similar to the effects of stimuliition of the para­
sympathetic nerve.He observed that both the injection 
of muscarine and the electrical stimulation of the 
vagus nerve lower the blood pressure of the cat. He 
put forward the hypothesis that electrical stimula­
tion of a nerve results in a local secretion of sub­
stances which interact with the effector organ, muscle 
or gland and thus induce their effects. It was already 
known that choline could produce a lowering of the 
blood pressure. Reid Hunt (l899) (З) provided evid­
ence of the existence of a substance in the supra­
renal gland, which lowers the blood pressure and was 
superior to choline in this respect, if its action 
was related to the choline content of the gland. He 
suggested that the adrenals contain an unstable choline 
ester with greater activity than choline. To invest­
igate this further he studied the effects of a series 
of choline esters synthesized by Taveau (4). One of 
those esters was acetylcholine, which is about 1000 -
10.000 times more potent than choline. 
The pharmacо-dynamic properties of acetylcholine 
(ACh) were re-investigated by Dale (1914) (5). He found 
that ACh has two distinct types of action on the cir-
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culation. A depressor, cardio-inhibitory action of 
the muscarinic type, unchanged by nicotine, but para­
lysed by atropine and a pressor action of the nicot­
inic type unaffected by atropine but abolished by 
excess of nicotine. 
The fact that injection of ACh results in a lower­
ing of the blood pressure of the same type as that 
seen after electrical stimulation of the vagus nerve, 
led Dale to the suggestion that ACh was responsible 
for the effects of stimulation of the parasympathetic 
nerve. For that reason he introduced the term para­
sympathomimetic for ACh and related compounds, e.g. 
muscarine, to characterize their effects. 
Seven years later Loewi (l92l) (6) produced exper­
imental evidence for the existence of a neurotrans­
mitter substance. lie observed that the stimulation of 
the vago-sympathetic trunks of a perfused isolated 
frog heart releases two antagonistic substances which, 
if perfused to a second heart, act there in the same 
way as the stimulation of the nerves. The second heart 
is inhibited by a perfusate obtained from the first 
heart which has been stopped by parasympathetic stimu­
lation. It is accelerated by the perfusate of a 
heart which has been accelerated by sympathetic stimu­
lation. The activity of the second heart is not 
changed by the perfusate of a heart in normal activity. 
The inhibitory substance produced by stimulation of 
the vagus he called "Vagusstoffe". The effect of this 
substance on the second heart can be prevented by 
atropine. This means that the action of the parasym­
pathetic transmitter on the effector organ is inhibit­
ed. By these experiments he demonstrated that the 
nerve action is transferred from the nerve to the 
effector organ by means of a chemical substance, a 
neurotransmitter. 
Loewi considered the"Vagusstoffe" to be identical 
with ACh. This substance was already synthesized by 
Bayer in I867 (?). Many authors tried to verify the 
experiments of Loewi on various organs of various 
species. Often the experiments gave a negative result. 
The cause appeared to be the rapid breakdown of ACh 
by an enzyme. Dale has assumed this already in 1914 
(5). Loewi and Navratil (l926) (β) detected choline 
esterase in extracts of frogs' hearts and found that 
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this enzyme could be inhibited by eserine. The iden­
tity of the "Vagusstoffe" with ACh was proved by 
Witanowski (1925) (9)· An argument against the iden­
tity of ACh with the chemical transmitter in the 
mammal was the absence of any evidence of its occur­
rence in the mammalian body. This was disposed of by 
the discovery of the choline esterase and more firmly 
by the isolation of ACh from ox spleen by Dale and 
Dudley (1929) (10). 
The situation became clear with the introduction of 
the leech muscle treated with eserine as a test object. 
With this muscle ACh in a concentration of 1/2O bill­
ions could be demonstrated (ll). This test enabled 
Feldberg and Krayer (1933) (l2) to demonstrate defin­
itely that the electrical stimulation of the vagus 
releases ACh in the coronary blood of mammals. 
1.2.1 P r i n c i p a l a c t i o n s o f 
a c e t y l c h o l i n e : 
slowing of the heart rate, 
weakening of the atrial contraction, 
relaxation of the smooth muscle fibres in vascular 
wall, 
contraction of the smooth muscle in the wall of 
the gastro-intestinal tract, 
relaxation of the sphincters of the gastro-intest­
inal tract, 
increased secretion by the salivary glands, 
contraction of the bronchioles, 
excitation at the myoneural junction and thus con­
traction of the striated muscle. 
1.2.2 B i o c h e m i s t r y o f a c e t y l -
c h о 1 i η e : 
ACh is synthesized in the nerve tissue from choline 
and "active acetate" by a specific enzyme, choline 
acetylase (іЗ)· 
/ C H 3 / C H 3 
CoA-C-CH3 + HO-CH2-CH2-N+-CH3 > CH3-C-0-CH2-CH2-N+-CH3 + CoA 
0 сн3 Ô сн3 
After release, ACh is very rapidly hydrolized with the 
aid of an enzyme (β), the acetylcholine esterase (14). 
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1.2.3 T h e m o d e o f a c t i o n o f 
a c e t y l c h o l i n e . 
There is still very little known about the mode of 
action. The following data are mainly derived from 
experiments in the region of the motoric endplate. 
By a nerve impulse ACh is released. It moves by 
diffusion to the post-synaptic cell membrane (l5)· 
The, receptor for ACh is located on this membrane (іб, 
17). After interaction with the receptor, the endplate 
membrane which in rest is polarized becomes depolar­
ized, the endplate potential decreases and simultane­
ously the permeability of the membrane for various 
ions increases (l8). 
There is strong evidence that the activation of 
the contractile elements in striated muscle is link­
ed to membrane polarization (l9). Perhaps the depolar­
ization permits or promotes the entrance of calcium 
ions and this calcium acts as a link between electric­
al and mechanical events in contraction (20). 
1.3 A d r e n a l i n e a n d n o r a d r e ­
n a l i n e . 
The question as to what substance is involved in the 
transmission of the nerve impulse from the nerve to 
the effector organ in the sympathetic system has in 
the course of the years been answered in various ways. 
Vulpian (I856) (21) discovered in the adrenals a 
substance which colours green with FeCl^ and on oxid­
ation produces characteristic colours. Although he 
did not know it, he was probably demonstrating for 
the first time the storage of catecholamines. 
Oliver and Schäfer (l895) (22) had found that a 
substance appears in extracts of the adrenal medulla 
and in the venous blood of the adrenal which after 
injection causes an increase of the heart rate and a 
constriction of the small arteries. Many research-
workers have worked on the isolation and elucidation 
of the structure of this active substance (23). Taka-
mine (24) was the first to secure the pure component, 
which he called "adrenine". After the synthesis (25) 
and the separation of the racemic compounds, the 
/-compound appeared to be identical with the active 
product of the adrenal extracts (26). 
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The structural formula of adrenine is 
О
ОН ^Н 
-C-C-ï/ 
сн3 
но 
So it is a secondary amine. Later on the name "adren­
aline" was introduced, which we shall henceforward 
use. 
The striking similarity between the responses to 
stimulation of the sympathetic nervous system and the 
effects of injection of adrenaline demonstrated by 
Lewandowsky (2?) and Langley (28) led Elliott (29) 
to the conclusion that "adrenine might then be the 
chemical stimulant liberated on each occasion, when 
the impulse arrives at the periphery". 
Barger and Dale (23) examined different compounds 
related chemically to adrenaline. Many of these sub­
stances on administration have the same results as 
stimulation of the sympathetic nerves. They are there­
fore called sympathomimetics. 
It appeared that the same effects caused by the 
stimulation of the sympathetic nerves could better 
be imitated by injection of primary amines such as 
arterenol than of secondary amines like adrenaline. 
That the excretion of a substance caused the trans­
mission of the impulse after stimulation of the nerve 
remained an hypothesis till 1921. As described earli­
er, Loewi (6) succeeded in proving this with the 
experiment of the two frog hearts (stimulation of the 
accelerator nerve of one heart resulting in a faster 
beating of the second). The substance which was liber­
ated was called by Loewi "Acceleransstoffe". By this 
experiment the chemical or humoral transmission of 
the impulse was proved. In the same year Cannon and 
Uridil (30) reported that electrical stimulation of 
the hepatic nerves is followed by the raising of a 
cat's heart rate and blood pressure. 
Cannon and Bacq (l93l) (3l) proved that stimulation 
of the sympathetic nerves of the cat resulted in the 
release of an adrenaline-like substance. It was called 
"sympathine". Many experiments seemed to support the 
view that sympathine was identical with adrenaline. 
Cannon and Rosenblueth (32) applied another pharmaco-
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logical test: the action of ergotoxine, which they 
expected would give results supporting the identity 
of sympathine and adrenaline. As first shown by Dale 
(ЗЗ) after injection of ergotoxine adrenaline produced 
a decrease instead of an increase of the blood 
pressure. 
If sympathine,released after stimulation of the sympa­
thetic nerve, were identical with adrenaline, a fall 
of the blood pressure under the influence of ergo­
toxine was to be expected. But after injection of 
ergotoxine the stimulation of the lumbar sympathetic 
nerve caused a prolonged rise of the blood pressure. 
They concluded that there was a difference between 
sympathine and adrenaline and also that the sympathine 
released by different nerves differs according to 
the nerve stimulated. 
Beside the question of whether sympathine and 
adrenaline are identical, there was still another 
difficulty which gave rise to speculation about the 
nature of the substance released by stimulation. This 
was that adrenaline gives opposite effects, excita­
tory and inhibitory. Some excitatory effects of adren­
aline are: vasoconstriction, nictating membrane con­
traction and cardio-acceleration. Some inhibitory 
effects of adrenaline are: vasodilatation, relaxation 
of the uterus of some species and intestinal relaxa­
tion. 
To explain this, Cannon and Rosenblueth (32) devel­
oped the following theory: 
Sympathetic fibres release a substance identical with 
adrenaline which combines in the effector cells with 
one of two specific receptive substances, E and I. 
According to the combination either of two circulat­
ing sympathines is produced, sympathine E or sympa­
thine I, which give a characteristic response either 
excitatory or inhibitory. The theory has not uni­
versally been accepted because, among other things, 
it was never possible to isolate sympathine E which 
must cause a purely excitatory action or sympathine 
I which causes a purely inhibitory action. 
On the contrary Bacq (З^) assumed that after stim­
ulation two substances are released, sympathine E, 
identical with arterenol and sympathine I, identical 
with adrenaline. This suggestion was supported by 
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experiments by Stehle and Ellsworth (35), Greer (36) 
and others. Bacq's suggestion did not receive enough 
attention and Cannon and Rosenblueth's theory remained 
the most important. It was even supported by the 
information given by Loewi (37) that the active sub­
stance in extracts of frogs' hearts was identical with 
adrenaline and the experiments of Gaddum and Kwiat-
kowski (1939) (З8) in which it appeared that the 
substance released upon stimulation of the cervical 
sympathetic ganglion resembled adrenaline. 
Von Euler (39) after an exact biological analysis 
of the extracts of sympathetic nerves came to the 
conclusion that the sympathetic substances present 
in these nerves have much more the character of 
arterenol than of adrenaline. Through the work of 
Tullar (40) -/-arterenol became available for pharma­
cological research. Now it appeared that -/-arterenol 
resembled more the effect of electrical stimulation 
of the sympathetic nerves than ^ -adrenaline. 
After this a lot of strongly contradictory publi­
cations followed concerning the difference in action 
of arterenol and adrenaline. One important cause for 
the incalculable situation is the fact that the action 
of arterenol and adrenaline depends not only on the 
kind of animal, but also on different organs and the 
physiological condition of the experimental animal 
(40a). Also the fact that sometimes .¿¿-arterenol and 
.¿¿-adrenaline and sometimes ./-arterenol and-/-adrenal-
ine is used has contributed to the often contradict-
ory ideas about the nature of the sympathetic trans-
mitter. 
In 1949 it appeared that synthetic and natural adren-
aline (extracted from the adrenal medulla) was not 
the same. Natural adrenaline contains about twenty 
percent of arterenol (4l). As not all authors mention 
which substance they use, the comparison of the re-
sults is difficult. It also appeared that the drug 
used for anaesthesia of the experimental animal has 
some influence on the results, as well as the manner 
of administration (42). It makes a difference whether 
the substances are administered i.v. or i.a. (43). 
If we consider all this, it can easily be under-
stood that often different results are reported with 
both components. An attempt to systemize the different 
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effects of arterenol and adrenaline has been under­
taken by Ah]quist (19^8) (44). Пе examined the action 
of 6 sympathomimetics on different organs. The main 
compounds were di -arterenol, ^ -adrenaline and N-iso-
propylarterenol. From his experiments he concluded 
that there are two "distinct types of adreno-tropic 
receptors ; the a-adreno-tropic receptor is associated 
with most of the excitatory functions and one im­
portant inhibitory function. The /b-adreno-tropic re­
ceptor is associated with most of the inhibitory 
functions and one excitatory function". Because ¿l -
adrenaline is the most active amine on both the a-
receptors and β-receptors, Ahlquist concluded that 
"there is only one adrenergic neurohormone, viz. 
epinephrine". 
Though this conclusion of Ahlquist's was wrong, 
the classification in a- and /3-receptors has some 
approximative value. In a later chapter the adrenergic 
receptors will be considered more thoroughly. 
From the work of Von Euler (l948) (44a), it was 
evident that arterenol was the main transmitter of 
the sympathetic nerve system. The main transmitter, 
because small quantities of adrenaline and dopamine 
are also demonstrated. The conclusion of Von Euler 
(45) was that "^-noradrenaline is the chief adrener­
gic nerve mediator in mammals". The release of adren­
aline and dopamine after stimulation of the post­
synaptic fibres is a result of the action of the 
chromaffine cells. Von Euler (45) supposed that ar­
terenol mainly played a rôle as a transmitter of ad-
renergic nerve fibres to the heart and vessels and 
that adrenaline mainly intermediates in metabolic 
processes. With this in mind E. Mohme Lundholm (46) 
ascertained the lactic acid percentage in different 
organs before and after administration of adrenaline. 
She came to the conclusion that there exists an anal-
ogy between the paralysis of smooth muscle under 
influence of adrenaline and the quantity of lactic 
acid produced via glycogenolysis under the influence 
of adrenaline. 
According to E. Mohme Lundholm (46) it is evident 
that the increase of the lactic acid percentage is 
sufficient to explain the paralysing action of adren-
aline, arterenol and isopropylarterenol. 
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So it is clear that there is no generally agreed 
theory concerning the role of arterenol and adrenaline 
in the organism. 
According to Minz (47): "It is very difficult to 
draw conclusions from all these complex observations, 
but pharmacological analysis demonstrates very clearly 
that neither epinephrine nor nor-epinephrine has 
exclusively stimulating or exclusively inhibitory 
properties. It is thus evident that the ratio of 
potency of one of these amines to the other bears no 
relation to whether an inhibitory or excitatory res-
ponse is involved". 
McGoodall and Kirshner (48) demonstrated with the 
aid of labeled tyrosine and dihydroxyphenylalanine 
that sympathetic nerves and ganglia can synthesize 
radioactive arterenol, but not adrenaline. This sup-
ports the idea, that arterenol is the neurotransmitter 
of the sympathetic nerve. 
1.3.1 M a i n a c t i o n s o f a d r e n -
a l i n e : 
augmentation of the atrial contraction, 
cardio-acceleration, 
constriction of the smooth muscle in the vascular 
wall, 
relaxation of the smooth muscle of the intestinal 
wall, 
contraction of the sphincters of the gastro-in-
testinal tract, 
relaxation of smooth muscle of the bronchioles, 
glycogenolysis resulting in an increase of the 
sugar level in the blood. 
1.3.2 B i o c h e m i s t r y o f a d r e n -
a l i n e a n d n o r a d r e n a l i n e . 
A n a b o l i s m . 
Recent evidence indicates that the bio-synthetic 
pathway to noradrenaline and adrenaline formation 
runs via dihydroxyphenylalanine and dihydroxyphen-
ylethylamine (dopamine ) (49). 
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Conjugation with sulphuric acid and with glucuronic 
acid (52, 53). 
Methylation of the meta-hydroxygroup with the 
process of oxidative deamination (5^, 55)· 
Oxidative deamination and excretion (56, 57, 58)· 
1.3.3 T h e m o d e o f a c t i o n o f 
a d r e n a l i n e . 
Adrenaline produces changes in the polarization 
of the membranes as does acetylcholine (59). Biilbring 
(60) observed the membrane potential of cells of the 
taenia coli of the guinea pig to fall after ACh and 
to rise after adrenaline, accompanied by a change in 
the permeability. 
1.4 H i s t a m i n e. 
Histamine was synthesized in 1907 by Windaus and 
Voght (6l). Barger and Dale (62) were able to isolate 
it from Ergot in I9IO and in 1911 (63) from the in-
testinal wall. It is possible that the histamine 
found in this way does not come from the Ergot or 
the intestinal wall, but from the putrefaction of 
microbes on the extracts. In 1927 the presence of 
histamine as a natural constituent of several organs: 
liver, lungs, muscles, was demonstrated beyond doubt 
by Best (64). Histamine is found in most tissues in 
a bound form, possibly with héparine (65). Histamine 
has a dilator effect on the capillaries of the dog, 
cat, rat and of man. Because the capillaries have no 
innervation,histamine must act here as a musculotrop-
ic substance. Perhaps it also acts as a transmitter 
in the nervous system. When the peripheral ends of 
sensory nerves are stimulated, histamine is released 
at the extremity in direct contact with the skin 
cells (66). Ungar (67) pointed out that besides chol-
inergic and adrenergic fibres histaminergic fibres 
also exist. 
Stimulation of the vagus results in an increase 
of the histamine-content of the gastric juice (68). 
After stimulation of the cervical sympathetic trunk 
the histamine-content in the blood increases (69)· 
Notwithstanding these experiments, it is not generally 
assumed that histamine is involved as a transmitter 
in the nervous system. 
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1.4.1 P r i n c i p a l a c t i o n s o f h i s ­
t a m i n e : 
Increasing of capillary wall permeability, 
dilatation of the capillaries, 
lowering of the blood pressure, 
constriction of the bronchioles, 
stimulation of the glands of external excretion, 
especially the gastric glands, 
involvement in anaphylactic shock. 
1.4.2 B i o c h e m i s t r y o f h i s t a m ­
i n e . 
The histamine present in the tissues of some parts 
of the nervous system is mainly formed locally by 
decarboxylation of /-histidine (70). 
-c-c-c 
NH
n
4 o H Ν Ν N: 
-/-histidine 
-C-C-NHn 
histamine 
The catabolism of histamine runs v ia severa l ways. 
Histamine can be i n a c t i v a t e d by a c e t y l a t i o n , under 
inf luence of CoA, into 4 [/3-acetyl-amino-ethyl] imi­
dazole (71) · 
-C-C-NH„ -NH-C-CH, 
V 
In the second place it is deaminated under influence 
of histaminase (72), via an aldehyde compound in 
imidazole acetic acid (73)· 
-C-C-NH, 
N. N 
-c-c=o 
ν 
I ,-c-c=o 
π ¿» 
•4/ 
Schayer (1956) (74) describes still another enzyme 
that has a double action on histamine, viz. a methyl-
ation and an oxydation. 
26 
1.5 S e r o t o n i n e +) 
Rapport (75) isolated a substance from blood serum 
which had two prime qualities. It constricted isolated 
perfused blood vessels and contracted isolated intes-
tinal strips. For 80 years a lot of very confusing 
literature had appeared about a variety of substances 
in serum with a vaso-activity (76). 
In 1948 a crystalline material containing an indole 
ring was obtained from pigs' serum (77)· This sub-
stance was 5-hydroxytryptamine (78). Hamlin and 
Fisher (79) synthesized the substance. The synthetic 
and natural serotonine were identical. 
Some years before, Vialli and.Erspamer (80) gave 
the name "enteramine" to a substance obtained from 
extracts of rabbits' stomach mucosa. The material 
originated from what they call "enterochromaffine 
cells". In I94O Erspamer considered the material to 
be a phenolic amine (8l). In 1946 Erspamer made it 
known that the substance was an indoleamine (82) and 
in 195- he and Asero suggested the identity of the 
enteramine with 5-hydroxytryptamine (83). 
There is some circumstantial evidence, but little 
direct proof, for the view that serotonine acts as a 
neurotransmitter in mammals. From observations of 
Rocha e Silva (l953) (84) the conclusion may be drawn 
that serotonine possibly acts upon the post-ganglionic 
cholinergic fibres of the intraneural nervous plexus 
of the guinea pig ileum. Holtz (85) supposed that be-
sides the "cholinergic" transmission in the plexus 
of Auerbach,there is possibly a"serotonergic" trans-
mission to the plexus of Meisner of the mucosa, ar-
ranged by serotonine. 
Holtz raised the following "conclusion": "The gang-
lia of the molluscs contain more serotonine than acetyl-
choline and phylogenetic there is a link between the 
ganglia of the invertebrates and the central nervous 
system of the vertebrates, thus it is to be under-
stood that the ganglia and the central nervous system 
of the latter also contain, besides cholinergic and 
noradrenergic, also serotonergic elements and trans-
mission occurs". 
+) Synonym: enteramine. Chemical name: 5-hydroxytryptamine, 5-H.T. 
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Brodie and Shore have suggested the idea that 
serotonine is the chemical transmitter of the central 
parasympathetic system with noradrenaline as the cen­
tral sympathetic transmitter (86). 
1.5.1 P r i n c i p a l a c t i o n s o f s e ­
r o t o n i n e : 
"amphibaric" on the blood pressure (87), 
increase of the heart rate, 
reduction of the bleeding time, 
stimulation of the intestine, 
constriction of the bronchioles, 
involvement in anaphylactic shock. 
1.5.2 B i o c h e m i s t r y o f s e r o t o n ­
i n e . 
Serotonine is an amine, which is formed through 
the conversion of tryptophan via 5-bydroxytryptophan 
(88). 
C-OH C-OH 
- C - C - N H 2 Г ^ i-C-C — • H O - f ^ i-C-C —* HO-r^*
4! i-C-C 
tryptophan 5-hydroxytryptophan S-hydroxytryptainine 
Serotonine is catabolized through mono-amino-oxy-
dase in 5-hydroxy-indole-acetaldehyde and with the 
aid of aldehyde dehydrogenase in 5-liydroxyindole-
acetic acid (89). 
о ^о 
но-Г "ì—i-C-C-NH,-*HO-r" ^ і—i-C-C* -*• HO-r^4! x-C-C* rc-c- H^Ho-Q^-c-cr^HO-Çç,-
OH 
5-hydroxytryptamine 5-hydroxy-indole- 5-hydroxy-indole-
acetaldehyde a c e t i c acid 
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C h a p t e r 2 
T Ü E O R E T I C A L C O N S I D E R A T I O N S . 
2.1 I n t r o d u c t i o n . 
As pointed out before, the aim of this thesis is 
the study of the relationship between the pharmaco-
logical action and the chemical structure in series 
of derivatives of the neurotransmitter substances. To 
discuss the pharmacological actions of chemical com-
pounds on a molecular level, the use of the term re-
ceptor is inevitable. As has been said, the receptors 
are those molecules or parts of them in the biologic-
al object with which the drug molecules have to 
interact in order to induce their effect. Although we 
have information as far as the chemical structure of 
the drug is concerned, we are at present not aware 
of the real nature of the receptors and hardly know 
even where they are located. The organ in the animal 
in which the effect is observed is not necessarily 
the place where the drug attacks or where the recep-
tors are located. Strychnine, for instance, causes 
spastic contractions of striated muscles. Its point 
of attack, however, is located in the central nervous 
system (l). The fact that the effect of a drug dis-
appears when a certain organ is removed gives no def-
inite information on the location of the receptors, 
nor does the accumulation of the drug in a certain 
tissue (2). Many reactions in the organism take place 
by means of enzymes. It is possible that in a number 
of cases the receptors for the drugs are located on 
enzymes. The inhibition of an enzyme by a drug in in 
vitro experiments does not allow of any conclusion as 
long as the concentrations of the drug used are not of 
the same order as the effective concentration of the 
drug in the living organism. 
The study of the relations between the chemical 
structure and the activity of drugs may possibly give 
some indirect information as to the nature of the 
receptors. If these relations are studied in the whole 
animal, the processes concerned with the absorption 
of the drug and its transport through the tissues 
will complicate the experiments and make conclusions 
more difficult. 
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In order for the greater part to exclude these pro­
cesses, we make use of isolated organs. 
It is useful to split up the total pharmacological 
process into three part-processes: 
1. The processes concerned with the relation between 
the dose of the drug and the concentration of the 
drug in the direct vicinity of the receptors, i.e. 
the biophase (З). These processes together repre­
sent the so-called drug-transference. 
2. The interaction of the drug with its specific re­
ceptors and the induction of the stimulus (4, 5)· 
3- The relationship between the stimulus and the ef­
fect obtained. 
2.2 D r u g - t r a n s f e r e n c e . 
If isolated organs are used, and this will be the 
case in all of our experiments, the influence of the 
drug - transference may be neglected and the concen­
tration in the biophase may be supposed to be largely 
linearly proportional to the concentration in the 
bathfluid. 
2.3 S t i m u l u s a n d e f f e c t . 
As far as the relationship between the stimulus 
and the effect is concerned, we shall start, for the 
sake of simplicity, with the hypothesis that there 
is a linear proportionality between them. This means 
that the effect is linearly proportional to the stim­
ulus or that instead of stimulus we may talk mathemat­
ically about effect. 
I n t e r a c t i o n o f d r u g s 
w i t h r e c e p t o r s . 
A f f i n i t y a n d i n t r i n s i c 
a c t i v i t y . 
The interaction between the drug and the 
receptors is supposed to be based on an equi­
librium as given by mass-law (6) or by the 
Langmuir adsorption isotherm (?). In both 
cases identical equations are obtained. 
For a drug A interacting with a receptor system H and 
producing its effect in an effector system Ejj, the 
2.4 
2.4.1 
R 
A 
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following equilibrium may be written: 
[R] + [A] ;=ï [RA] 
The dissociation-constant, Кд, of the drug-recep­
tor complex, RA, or its reverse, the association-
constant, is a measure for the affinity between drug 
and receptors. When we call the total amount of re­
ceptors: r, the fraction which is occupied by the drug 
A in the presence of a certain concentration [A] be­
comes:
 + ) 
[RA]/r = 1/(1 + KA/[A]) (2-1) 
where r is equal to [R] + [RA] 
For the effect, Ед, of a substance A expressed as a 
fraction of the maximal effect, Ещ, that is possible 
with the biological object concerned we may write: 
EA / Eiii = ^ * 1 + Кд/ІЛІ) (2-2) 
The proportionality constant, a, is called the in­
trinsic activity (l3, 14)· Various drugs may have 
various intrinsic activities. While the relation be­
tween the quantity of drug-receptor complex and the 
stimulus depends on the drug in question, the relation 
between the stimulus and the effect is supposed to 
be independent of the drug concerned. A certain stim­
ulus always correlates with the same effect. 
As a matter of fact more complicated relations may 
be introduced, but it is a good rule to keep a theory 
as simple as possible and only to make it more com­
plicated if the need arises from the experimental 
data. 
As may be seen from the theoretical curves cal­
culated from eq. 2-2 represented in fig. 2-1 (il), a 
change in the dissociation constant Кд or in the af­
finity results in a parallel shift of the curves. A 
change in the intrinsic activity results in a varia­
tion of the maximal height and the slope of the curves. 
+) Derivations of the formulae used «ill be found elsewhere (4, 8, 
9, 10, 11). 
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The intrinsic activity of the compounds which give 
the maximal effect with the biological object con­
cerned, is given the numerical value of one. A gradual 
IO*1 I 10 [A] 
Fig. 2*1 Theoretical log c o n c e n t r a t i o n - r e s p o n s e curves for compounds A 
with various values for the intrinsic activity» c, and the a f ­
finity, І М д . (eq. 2 - 2 ) . 
Note a shift of the curves with a variation in the affinity and 
a decline in the maximal height and in the slope with a decrease 
in the intrinsic activity. 
Кд = 1 except for where Кд = 0.25 and where Кд = 4. 
decrease in intrinsic activity from one to zero re­
sults in a gradual change from active compounds into 
"inactive" ones. 
2.4.1.1 E q u i a c t i v e d o s e s . 
Equiactive doses are doses of drugs producing equal 
effects; they are a measure much used in the litera­
ture for comparing the activity of compounds. From 
fig. 2-1 it may be seen that a comparison of equi­
active doses may lead to wrong conclusions as far as 
the activity of drugs is concerned. Compare, for ex­
ample, two compounds that seem to have equal activi­
ties at a certain dose. The compound with a value for 
Кд= 1 and an intrinsic activity 0.6 and the compound 
with Кд = 4 and an intrinsic activity = 1. It can be 
seen that for values of Ед/Ещ below 0.42 the first 
compound will be found to be the more active one. 
For the value 0.42 they are equally active, while for 
values of Ед/Ещ > 0.42 the second compound will be 
found to be the more active. 
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In fact the situation is such that as far as affinity 
is concerned, the first compound really is the more 
active, it has the higher affinity to the receptors, 
while as far as the intrinsic activity is concerned, 
the second is more active and consequently the max­
imal effect to be obtained with it is higher than 
that obtained with the first compound. 
2.4.2 C o m p e t i t i v e a n t a g o n i s m . 
As f or the "inactive" compounds, only the intrinsic 
activity is zero, while there is still an affinity to 
the specific receptors, these compounds will occupy 
the receptors without producing an effect. If, how­
ever, such a compound is combined with an agonist -
a compound with an intrinsic activity > 0 - its pre­
sence will manifest itself by a certain hindrance of 
the occupation of the receptor by the molecules of 
the agonist. Both compounds compete for the same re­
ceptors. In the presence of the "inactive" compound 
higher doses of the agonist will be necessary to ob­
tain a certain effect than in the absence of the "in­
active" compound. 
E The compound with an intrinsic activity 0 |R behaves as a competitive antagonist of the 
R agonist. The relation between two drugs com-
/ \ peting for the same receptor system is re-
A в presented by the following equilibria: 
[R] + [Β] ί ϋ [RB] 
[R] + [A] 5=» [RA] 
Drug A as well as drug В interacts in a reversible 
way with the specific receptors H. The effect of a 
combination of A and В depends on their intrinsic 
activities and on the fraction of the receptors oc­
cupied by each of them: 
W ^ * a[RA]/[r] + /M/M (2-3) 
or 
EAB/EB = a/{l + (1 + [B]/KB) KA/[A]} + /3/{l + (1 + [A]/KA) Кв/[в]} 
(2-4) 
a And β are the intrinsic activities of the Drug A 
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and В respectively and Кд and Кц the dissociation 
constants of the corresponding drug-receptor complexes 
(ll, 14). If in this equation 0 is substituted for p, 
it represents the combination of an agonistic drug A 
in the presence of a competitive antagonist B. Then 
it becomes identical with the well-known equation for 
competitive antagonism (6). Theoretical concentration-
response curves for this combination calculated from 
eq. 2-4 are represented in fig. 2-2 (ll). The com­
petitive antagonistic action of В manifests itself 
^ Λ ™ 1 
1.0 -
Q8-
Q6 -
0.4 -
Q? -
r " —ι τ 
I0H I 10 [A] 
Fig. 2-2 Theoretical log concentratι on-re spense curves tor serial con­
centrations of the agonist A la = 1, Кд = 1) ¡η the presence of 
constant concentrations of a competitive antagonist В iß - 0, Κβ 
= 1 ) . (eq. 2-41. 
Note the parallel shift of the curve for the agonist as induced 
by the competitive antagonist. 
as a parallel shift in the concentration-response 
curves for A. An increase of the concentration of the 
drug A may always overcome the inhibitive action of 
B; the antagonism is surmountable. 
2.4.2.1 C o m p e t i t i v e d u a l i s m i n 
e f f e c t . 
Especially interesting is the combination of a 
drug A with a high intrinsic activity, α = 1, with a 
drug В with an intermediate intrinsic activity, β < 1. 
If concentration-response curves for the compound A 
are made in the presence of various concentrations 
of the compound В and if eventually the concentrat­
ions of A become high enough, a full response, that 
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of A, will always be obtained. The more of the compound 
В there is present however, the more of the compound 
A will be necessary. Fig. 2-3 (ll) represents theo­
retical log concentration-response curves for this 
combination as calculated from eq. 2-4. 
τ 1 г 
I 10 I0J [A] 
Fig. 2-3 Theoretical log concentration-response curves for serial concen-
t r a t i o n s o f the agonist A (a = 1, Кд = 1) in the presence of con­
stant concentrations of the competitive dualist В (/3 = 0.4, Kg = 
1 ) . leq. 2-ЧІ. 
Note agonistic properties of substance В in the left part of the 
figure and a c o m p e t i t i o n in the right part of the figure as a 
shift of the curve for the agonist· 
With lower doses of A, the presence of В results 
in an increase of the effect. With higher doses of A 
the presence of В results in a decrease of the ef­
fect. There is a dualism in the action of compound 
B, viz. an agonistic and a competitive antagonistic 
one. The shift in the log concentration - response 
curves for the agonist in the presence of a competi­
tive antagonist as represented in fig. 2-2 and 2-3 de­
pends on the concentration of the antagonist and its 
affinity to the specific receptors (l2, 13)· 
To sum up: depending on the intrinsic activity, in 
a series of compounds interacting with the same spe­
cific receptors, there may be a differentiation be­
tween: 
1. agonist, the compounds with a high intrinsic ac­
tivity, 
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2. competitive antagonists, the compounds with an in­
trinsic activity zero, 
3. partial agonists (5), the compounds with a dualist­
ic behaviour, those with an intermediate intrinsic 
activity. They might be called partial antagonists 
as well. These compounds may reveal agonistic as well 
as competitive antagonistic properties. The agonists 
and the competitive antagonists are often called mi-
metics and lytics respectively. In a certain way it is 
indifferent which of the compounds is called the ag­
onist or the competitive antagonist. As a rule the 
mimetics of the neurotransmitters are called the ag­
onists. 
2.4.3 N o n - c o m p e t i t i v e a n t a g ­
o n i s m . 
In the case of a competitive interaction between 
two drugs A and В as discussed above, both drugs 
interact with the same receptor system. If we take 
into account that after occupation of the receptors 
a whole chain of reactions or events takes place for 
the induction of the stimulus and the final response, 
it will be clear that a drug may interfere with the 
effect of another drug without interacting with the 
same receptors. In that case the interaction is not 
competitive but non-competitive. 
E R For the non-competitive antagonism the 
1
 effectivity of the stimulus with respect 
5 " γ to the effect is decreased as a result of 
I i the interaction of the antagonistic drug 
A в
 В with receptor R». 
The combined effect, of an agonist A (a > θ) and a 
non-competitive antagonist B, as a fraction of Ещ, may 
be represented by eq. 2-5. 
EAB,/Eii. = a / ( 1 + ^ЬЛі * (1 + /3·)[Β]/Κ·
Β
}/(1 + [BJ/K'B) 
or 
Ε
ΑΒ·
/Ε
ΙΡ = W ^ 1 + (1 + /Ö^W/K'^/d + [В]/К'
в
) (2-5) 
in which ь ' is the intrinsic activity of В, [B] the 
concentration of the non-competitive antagonist and 
Kg the dissociation constant of the drug-receptor 
complex R'B. 
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Ед/Е
т
 is the effect of A in the absence of the non­
competitive antagonist (eq. 2-2). If β* = -1, eq. 
(2-5) may be reduced to 
EA/EAB· - M / K , B + 1 ( 2 - 6 ) 
The effect of the agonist is reduced in the pres­
ence of the non-competitive antagonist by a factor 
1 + [Β]/Κ·
Β
. 
In the presence of a non-competitive antagonist a 
decline in the maximal height and in the slopes of 
the curves of the agonist takes place (13, iM· 
Fig. 2-4 (ll) gives theoretical concentration-response 
curves as calculated from eq. 2-5. 
ΜΕ*, , 
1.0 -
08 -
06 -
04 
0.? 
I 0 H I 10 [ A ] 
F i g . 2 - 4 T h e o r e t i c a l l o g c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r s e r i a l c o n ­
c e n t r a t i o n s o f t h e a g o n i s t A ( a = 1 , Кд = 1) i n t h e p r e s e n c e o f 
c o n s t a n t c o n c e n t r a t i o n s o f a n o n - c o m p e t i t i v e a n t a g o n i s t В (/3' = 
- 1 , Κ ·
Β
 = 1 ) . ( e q . 2 - 5 ) . 
N o t e t h e d e c l i n e o f t h e m a x i m a l h e i g h t a n d t h e s l o p e o f t h e c u r v e 
f o r t h e a g o n i s t a s i n d u c e d by t h e n o n - c o m p e t i t i v e a n t a g o n i s t . 
Whereas in the case of a competitive-antagonism a 
parallel shift in the curves is obtained (fig. 2-2), 
in the case of a non-competitive antagonism a gradual 
reduction of the curves with an increase of the con­
centration of the antagonist takes place. For lower 
concentrations of agonist and non-competitive antag­
onist the antagonism is to a certain degree sur­
mountable. For higher concentrations of agonist or 
non-competitive antagonist, the antagonism is insur-
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niountable. This is often used as a criterion for non­
competitive antagonism as compared with competitive 
antagonism, which is always surmountable. 
2.4.4 M u l t i p l e A n t a g o n i s m . 
There is no special reason why certain drugs, de­
pending on their chemical properties, should not act 
as competitive as well as non-competitive antagonists. 
This means that at a certain concentration the drug, 
E B, manifests a competitive antagonistic 
I action, because of its affinity to the 
в - R* specific receptors R for the agonist, A, 
Τ \T while at higher concentrations a non-com-
A в petitive interaction is also involved, be­
cause of an affinity to another group of 
receptors, R1. This is in fact a combination of both 
types of antagonism represented in eq. 2-3 and 2-5 
and in fig. 2-2 and 2-4. 
E A B B y E m 
1.0 -
0.8 -
0.6 -
0t4- -
0.2 -
1 f г 
I IO i o 2 [ A ] 
F i g . 2 - 5 T h e o r e t i c a l log c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r s e r i a l c o n c e n ­
t r a t i o n s o f t h e a g o n i s t A (a = 1 , к д = 1 ) in t h e p r e s e n c e o f 
c o n s t a n t c o n c e n t r a t i o n s o f t h e d r u g В (/3 = 0, /3' = - 1 , K g = 1, 
K' g = 4 0 ) , e x h i b i t i n g a d u a l i s m in a n t a g o n i s m , ( e q . 2 - 7 ) . 
N o t e t h e p a r a l l e l s h i f t o f t h e c u r v e for t h e a g o n i s t i n d u c e d by 
t h e c o m p e t i t i v e a c t i o n o f the a n t a g o n i s t , o n w h i c h a d e c l i n e o f 
the m a x i m a l h e i g h t and t h e s l o p e o f t h e c u r v e is s u p e r i m p o s e d by 
the n o n - c o m p e t i t i v e a c t i o n o f t h e a n t a g o n i s t . 
The action of a compound В with a multiple type of 
antagonism, competitive and non-competitive respect-
[Β] = 0 ι 2 •* β 16 32 
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i v e l y , may he represented Ъу eq. 2-7. 
Ε
ΑΒΒ·
/Ε
ιη
 =
 ^і
1 + (1 +
 [Ч/^ WW) · 1/(1 + W*'** (2-7) 
in which the intrinsic activity of Α, α = 1, the in­
trinsic activity of D as a competitive antagonist, 
/0=0 and the intrinsic activity of В as a non-com­
petitive antagonist ¿Ü1 = -1 (ll). Depending on the 
value KB/K'B the competitive or the non-comuetitive 
component in antagonism dominates. Fig. 2-5 (ll) 
gives theoretical concentration-response curves as 
calculated from eq. 2-7· 
2.5 E v a l u a t i o n o f d r u g s . 
2.5.1 E v a l u a t i o n o f a g o n i s t s . 
For the evaluation of agonistic compounds, pD2 
values are used.The pD2 value is the negative logarithm 
of the molar concentration of a drug that gives an 
effect which is 50% of its maximal effect (lO). From 
eq. 2-2 it follows that if Ед/Едш = i, K A = [A] and 
pD2 = - log. Кд. The pD2 value is a measure for the 
affinity of the agonists to their specific receptors. 
An increase of the pD2 value means an increase in the 
affinity. 
2.5.2 E v a l u a t i o n o f c o m p e t i t ­
i v e a n t a g o n i s t s . 
A procedure to evaluate a competitive antagonist 
is given hy Schild (l5)· He introduced the so-called 
pA
x
 value, which is the negative logarithm of the 
molar concentration of a competitive antagonist which 
will reduce the effect of a multiple dose (x) of an 
active drug to that of a single dose, thus the dose 
of A in the presence of B, [Ajg, gives an effect 
equal to the dose of A in the absence of B, [A]. 
From eq. (2-2) and (2-4) it follows that: 
[АУ [A] = [B]/KB • l - x (2-8) 
Where χ = 2 it obtains that [A]B/[A] = 2, then K B = 
[B], therefore pA2 = - log. Kg. The pA2 value is a 
measure for the affinity of a competitive antagonist 
to its specific receptors. 
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An increase ID the pA2 values means an increase in the 
affinity. From the eq. (2-8) it follows that: 
log (x - 1) = - log KB - ρΑχ (2-9) 
I f t h e r e a c t i o n s b e t w e e n t h e d r u g s and r e c e p t o r s 
a r e of a h i g h e r o r d e r 
R + nA ^Г± RAJJ 
R + mB ZI* RB
m
 η and m > 1 
e q . ( 2 - 9 ) b e c o m e s 
log (xn - 1) = - log KB - ιηρΑχ (2-10) 
When log (x - l) is plotted against ρΑ
χ
 a curve with 
an asympthote of 43° is expected, at least in the case 
where both reactions between the drugs and the re­
ceptors are of the same order, therefore if n/m «= 1 
(10, 16). The curve will be straight if η = m = 1. 
There will be a slight deviation for lower values 
of pA
x
 if η = m = 2 (IO). 
2.5.3 E v a l u a t i o n o f n o n - c o m ­
p e t i t i v e a n t a g o n i s t s « 
For the evaluation of non-competitive antagonists 
the p D ^ values are used (io). These are the negative 
logarithms of the molar concentrations of a non-com­
petitive antagonist, which reduces the effect of a 
concentration of an agonist to 50% of the original 
value. From eq. (2-5) it follows that if ЕДДІ/ЕД = 
-§, [В] = Kj) and pD'2 = - log. Kg. The p D ^ value is a 
measure for the affinity of the non-competitive antag­
onist to its specific receptors. 
For compounds with a multiple antagonism pA2 as 
well as p D ^ values may be determined. 
2.6 C o n c l u d i n g r e m a r k s . 
In the following chapters a number of experiments 
with some series of derivatives of neurotransmitters 
will be described. All experiments have been perform­
ed with isolated organs.Nevertheless it will be clear 
to the reader that the premises used in our theoretic­
al considerations are far too simple compared with the 
complexity in the experimental situation. This means 
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that in the first instance a qualitative approach 
between theory and experiment may chiefly be expect-
ed. In a later chapter we shall elaborate the theory 
a little more,in order to meet the requirements that 
may evolve from the experiments. 
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C h a p t e r 3 
D E R I V A T I V E S O F S O M E N E U R O ­
T R A N S M I T T E R S . 
3.1 I n t r o d u c t i o n . 
From the t h e o r e t i c a l c o n s i d e r a t i o n s i t follows t h a t 
as far as an agonis t and i t s competi t ive antagoni s t 
are concerned, both have in common an a f f i n i t y to the 
same s p e c i f i c r e c e p t o r s . They d i f f e r in t h e i r i n t r i n -
''•'/ъ contraction jejunum r a t -
100 
vcu deferens rat-
Mc5 0 1 2 . 1 0 " г т м 
10" 10" 10" - 6 l o " 4 IO"3 1 0 _ г 
m м Acetyl Choline 
9"·«/ contraction jejunum guinea pig 1 uterus rat 
100 
10" 
m M Arterenol 
6-Melhylgramine Ó 
т м Histamine 
10" 
í f, 
О 5.3 .Ю-3 
f I т м 
10" 10" 
т м Serotonin 
F i g . 3 - 2 C u m u l a t i v e l o y c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r a c e t y l c h o l i n e , 
a r t e r e n o l , h i s t a m i ne and s e r o t o n i ne + ) i n t h e p r e s e n c e o f c o n s t a n t 
c o n c e n t r a t i o n s o f r e l a t e d s p e c i f i c a n t a g o n i s t s . 
N o t e t h e p a r a l l e l s h i f t o f t h e c u r v e s w h i c h i n d i c a t e s a c o m p e t ­
i t i v e a n t a g o n i s m . 
s i c a c t i v i t y . Discussing the r e l a t i o n s h i p between 
chemical s t r u c t u r e and a c t i v i t y of drugs, we may ex-
+ ) Modified after Gadduin (1). 
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pect that compounds that have an affinity to a common 
receptor system will have a certain similarity in 
their chemical structure or at least in their physico-
chemical properties. It is these properties which de­
termine whether and how the interaction with the re­
ceptors will take place. 
In fig. 3-1 experimental concentration-response 
curves for four couples of agonists and their corres­
ponding competitive antagonists are given. The char-
acteriatics of the concentration-response curves 
correspond with those expected from the theory for a 
competitive relation. Compare fig. 3-1 with fig. 2-2. 
A comparison of the chemical structures reveals 
that especially as far as acetylcholine, arterenol 
and serotonine are concerned, there is a clear resem­
blance between agonist and antagonist. For histamine 
and neobenodine the resemblance is less clear (see 
following formulae). 
HO 
C-C-O-C-C-NQ: 
o
 c 
ACh 
HO r\ C-C-N 
О 
H 
arterenol 
HO-/ 8 
Л 
с— 
ύ-c 
¿ — ¿ — 
atropine 
HO 
HO 
Mc5 
^ 
C—C-C-N 
II 
с histamine 
-C-C—N 
Mrotonin· 
-O-C-:-C—К 
neobenodine O -meUiylgruiiiiiw 
In this chapter experiments will be discussed aim­
ing at a gradual change in the chemical structure of 
some neurotransmitting substances in such a way that 
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a gradual change to the corresj)onding competitive 
antagonists takes place. As may be seen from the form-
ulae given above, the chemical relation between arter-
enol and N-"isobutylphenyl,l-arterenol (Me 5) and be-
tween acetylcholine (ACh) and atropine,is quite clear. 
These couples oi drugs strongly suggest the existence 
of biologically active intermediates. For this reason 
our study will concentrate in the first instance on 
derivatives of arterenol and of acetylcholine. 
3.2 A r t e r e n o l a n d d e r i v a t i v e s . 
As mentioned before, N-"isobutylphenyl"-arterfcnol 
(Me 5), obtained by substitution of an aralkyl growp 
on the nitrogen atom, behaves as a competitive antag-
onist of arterenol, therefore as a sympatholytic. 
The questions arise: "What course does the gradual 
change take from agonist,sympathomimetic, to compet-
itive antagonist, sympatholytic?" "How do the com-
pounds behave in the transition from mimetics to lyt-
ics?" 
Especially suitable for our investigations are 
the derivatives obtained from arterenol and nor-sym-
patol by substitution of one hydrogen atom by alkyl 
or aralkyl groups, with a gradually increasing number 
of carbon atoms, on the nitrogen atom. These series 
of compounds have the following formulae: 
arterenol series: HO-/ Vc-C-N-R 
sympatol series: HO-^ Vç-C-N-R 
V
— ' OH 
in which R may be an alkyl or an aralkyl group (2). 
The various derivatives will be mentioned as N-alkyl-
arterenol and N-alkylsympatol, e.g. N-methylarterenol 
(adrenaline), N-butylsympatol, etc. 
3.2.І L i t e r a t u r e s u r v e y . 
Although there is a large body of experimental data 
available on the relationship between structure and 
activity of arterenol and derivatives - more than 
6OO derivatives were studied -, the questions mention­
ed above have not yet been answered. 
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Within the scope of this thesis it is not possible to 
review all known compounds. Only of those data that 
are of direct interest to our problem will a short 
review be given. A number of review articles covers 
most of these data (3, k, 5, 6, 7, 8, 8a, 8b). 
It is obvious from the reviews mentioned that as 
a rule the sympathomimetic activity of the various 
compounds, suchas the raising of the blood pressure, 
diminishes after introduction of alkyl groups with 
more than one carbon atom on the nitrogen. As a rule 
catechol derivatives (arterenol,adrenaline,etc.) are 
more active than the derivatives with only one phen­
olic OH-group (8, 9). The phenyl-ethylamines without 
phenolic ΟΠ-groups also behave as sympathomimetics. 
They are less active than the sympatols. 
Probably, however, the effects they induce do not 
result from their interaction with the specific re­
ceptors for arterenol and adrenaline, but from a re­
lease of both arterenol and adrenaline or only one of 
them from physiological storages (lO). 
With the introduction of larger alkyl groups on the 
nitrogen atom, derivatives are obtained which show a 
reverse in the type of action. N-isopropylarterenol 
and N-propylarterenol cause a lowering of the blood 
pressure instead of a rise as given by arterenol (З)· 
On the isolated uterus they cause a relaxation instead 
of a contraction as observed with arterenol and adre­
naline (4). These phenomena were observed for the ar­
terenol as well as for the sympatol derivatives (8). 
Many data in the literature are concerned with the 
effects on the blood pressure. Although from the study 
of these effects qualitative information on the sym­
pathetic drugs may be obtained, because of the very 
complex nature of the blood pressure, it is not very 
suitable for a study on the relationship between 
structure and activity. 
The blood pressure is dependent on many factors as 
the constriction and dilatation on the various parts 
of the vascular bed, which determine the peripheral 
resistance and venous return, which together with the 
heart action determines the cardiac output (ll). 
The various compounds act in a different way as far 
as the various components contributing to the blood 
pressure are concerned, so that adrenaline causes a 
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constriction of the arterioles in the splanchnic area 
and the skin. In the vessels of the skeletal muscles 
it may cause a constriction, often, however, a dilat-
ation is obtained, dependent on the route of injec-
tion, the vaso-motor tone in the muscle and the dose 
administered (12).Arterenol practically always causes 
a constriction in the various vessels (l3)· 
Also as far as the influence on the heart action is 
copcerned, adrenaline and arterenol differ. The first 
compound, ior instance, causes an increase of the fre-
quency. This is not or to a much less degree the case 
with arterenol (14). 
Besides these complications, a number of feed-backs 
in the regulation of the circulation, in which the 
sympathetic as well as the parasympathetic part of 
the autonor.ious nervous system play a rôle, is also 
involved (ll) . 
This is the reason why the effects measured on the 
blood pressure are so complex in their origin that 
they are of little use in a quantitative approach of 
the relationship between structure and activity. 
Although, from studies on the blood pressure, an 
indication was obtained of a gradual change from sym-
pathomimetics to sympatholytics in the series of N-
substituted arterenol derivatives -the object of our 
investigation - a definite proof for such a relation-
ship was not given (15)· 
З.2.2 O p t i c a l i s o m e r s . 
Especially interesting is the fact that the optic­
al isomers of arterenol and adrenaline differ in their 
activity. For instance -/-arterenol is 4 - 60 times as 
active as the ^ -isomer (l6)and /-adrenaline is about 
12 - 60 times more potent than the ¿-isomer (3), de-
pendent on the biological objects. This difference 
in the activity for the optical isomers points to the 
necessity of a high degree of complementarity between 
drug and receptor. Small differences in the configur-
ation of the drug molecule essentially influence its 
binding to the specific receptor. 
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3 . 2 . 3 S y m p a t h o l y t i c s . 
For most of t h e s y m p a t h o l y t i c s used i n g e n e r a l 
p r a c t i c e t h e r e i s no c l e a r r e l a t i o n s h i p b e t v e e n t h e i r 
c h e m i c a l s t r u c t u r e s and t h o s e of t h e s y m p a t h o m i m e t i c s . 
See f o l l o w i n g f o r m u l a e : 
HO-^ V c - C - N - C - C - С Д > Nylidrinum. 
ОН С С 
HO-( Vc-C-N-C-C-O-/ S Duvadilan. 
О 
T T V Piperoxanuœ. 
Opilon. 
c-o-c ^ c' 
и ^ C O 
Ю 
O' 
но" 
Ν—С—С N Phentolaminum. 
Ν 
О' 
о-
^N-C-C-Cl 
С 
Dibenamine. 
Only for Nylidrinum and Duvadilan is the relation 
clear.The sympatholytics of the ß-haloalkylamine type 
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occupy a special place (l?, 18). These compounds are 
so-called irreversible blocking agents. They are 
chemically related to nitrogen mustard and block the 
specific receptors for the sympathomimetics by a chem-
ical binding which is not reversible. 
3.2.4 E q u i a c t i v e d o s e s c o n t r a 
i n t r i n s i c a c t i v i t y a n d 
a f f i n i t y . 
Most data on activity found in the literature con-
cern relative activities, based on the comparison of 
equiactive doses. As mentioned already the comparison 
of equiactive doses is of no use for a differentiation 
between affinity and intrinsic activity, which is es-
sential in our approach to the problem. Only concen-
tration-response curves are an effective source of 
information. The experiments described in the follow-
ing pages have been performed on simple isolated org-
ans. An extra advantage is that many factors in-
fluencing the concentration in the biophase, as ab-
sorption, transport, metabolism, conjugation, excre-
tion have then for the greater part been eliminated. 
3.2.5 M e t h o d s a n d m a t e r i a l s . 
For a study of sympathomimetic drugs on isolated 
systems, various organs can be considered. The liter-
ature of the subject mentions as such the seminal 
vesicle of the rat (l9), the aorta atrip of the rabbit 
(20), the vas deferens of the guinea pig (2l), the 
spleen (22) and the uterus of the rabbit (23). As our 
aim is to obtain concentration-response curves, those 
organs that undergo a contraction under influence of 
the sympathomimetics are preferred. 
Various organs were tested by us, viz. strips of 
the isolated spleen of various animals, the aorta 
strip of the rabbit, the seminal vesicle of the rat 
and the vas deferens of the rat. The vas deferens of 
the rat appeared to be the most suitable. It is easy 
to handle and very constant as far as concerns the 
effects obtained. There is a high degree of reproduce-
ability and the time necessary to obtain a complete 
cumulative dose-response curve is relatively short. 
The same obtains for the rinsing out of the drug. 
52 
With one organ a series of ten dose-response curves 
can easily be obtained. The disadvantage of the aorta 
strip of the rabbit is the fact that it has to be 
adapted for two hours or longer before it can be used. 
The time necessary to obtain a dose-response curve 
and to rinse out the drug is also very long. The same 
obtains for the isolated spleen, the intervals of 
time necessary to obtain the response and especially 
for rinsing were too long for our purpose. 
After carefully removing the vasa deferentia from 
young adult rats, they were suspended in a bath con­
taining 10 ml. of Tyrode solution, through which air 
was bubbled, while the temperature was kept at 35° C. 
Composition of Tyrode: S.Og.NaCl, 0.2 g. KCl, 0.2 g. 
СаСІ2, 0.1 g. MgCl2, 1.0 g. NalK^, 0.05 g. Nal^PO/j, 
1 g. glucose, U2O ad 1 1. 
Contractions were recorded isotonically by a lightly 
loaded lever on a sooted drum. Cumulative dose-res­
ponse curves were made by adding quantities of the 
drug in the following sequence: a, a, 2a, 4a, etc., 
thus doubling, redoubling, etc. of the concentration 
without intermediate rinsing. Each concentration was 
left in contact with the organ till no further con­
traction was observed. Then the concentration was 
doubled by adding the subsequent dose. Finally when a 
following dose no longer increased the contraction, 
the drug was rinsed out and a dose-response curve was 
obtained.The time interval between the various doses 
is about 60" - 90", the time of rinsing about 20' - 40'. 
Log concentration-response curves were calculated by 
expressing the effect of each concentration of the 
drug in percentages of the maximal effect to be ob­
tained with arterenol. 
The curves obtained with different organs vary 
for their pD2 value; they are "parallel" within close 
limits. Fig. 3-2a represents the concentration-res­
ponse curves of a large number of reference curves 
of the experiments described in the following pages. 
If concentration-response curves for arterenol ob­
tained with one and the same organ are compared, the 
variation in pD2 is much smaller, see fig. 3-2Ъ. 
The affinity of arterenol is expressed in terma 
of a mean pD2 value, calculated from a large number 
(lOO) of concentration-response curves. 
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The affinity of the other agonists are expressed in 
relativepD2 values using arterenol as a standard drug. 
0/o contraction 1 1 
ΙΟΟη 
80-
60-
40-
20-
to-3 10"¿ IO"1 IO"3 IO"2 IO"1 
тпм A r t e r e n o l т м Arterenol 
r i g . 3-2» а-b C u m u l a t i v e loj c o n c e n t r a t i o n - r e spon se c u r v e s for a r t e r e n o l 
tested on the vas d e f e r e n s of the rat. 
The r e f e r e n c e c u r v e s of the e x p e r i m e n t s in t h i s c h a p t e r are 
c o l l e c t e d in fig. 3-2a. C u r v e s o b t a i n e d w i t h one vas d e f e r e n s 
of the rat, are collected in fig. 3 - 2 b . 
N o t e the v a r i a t i o n s of the c u r v e s on the d i f f e r e n t vasa d e f -
e r e n t i a and the much s m a l l e r v a r i a t i o n of the c u r v e s on one 
o r g a n . 
The affinity of competitive antagonists is express­
ed in terms of the mean pAo values. The pA2 values 
have been calculated from the degree of shifting,x, 
according to eq. (2-8). 
3.2.6 E x p e r i m e n t s . 
As was said in the case of an analysis of the re­
lationship between chemical structure and activity, 
concentration-response curves are essential. Fig. 3-3 
and 3-^ represent cumulative log concentration-res­
ponse curves for a series of arterenol derivatives 
and a series of sympatol derivatives. 
From these concentration-response curves it can be 
seen that with an increase in the number of carbon 
atoms in the substituent on the nitrogen atom, there 
is a gradual change from the active compounds to "in­
active" ones. On the basis of the theory and data 
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% contraction 
100 
8 0 -
Fîg. 3-3 Cumulative log c o n c e n t r a t i o n - r e s p o n se curves for a series of 
arterenol homologues as tested on the vas deferens of the rat. 
Note the p r o g r e s s i v e decrease of the affinity and the gradual 
change from active to " i n a c t i v e " compounds with elongation of 
the alkyl chain on the N-atom. 
% contraction 
100 
-^ V C - C - N - R 
KIM 
Fig. }-4 C u m u l a t i v e iog c o n c e n t r a t i o n - r e s p o n s e curves for a series of 
sympatol h o m o l o g u e s as tested on the vas d e f e r e n s of the rat. 
Arterenol is the referen c e s u b s t a n c e (see text!. 
Note the p r o g r e s s i v e d e c l i n e of the a f f i n i t y and the gradual 
change from a c t i v e to " i n a c t i v e " c o m p o u n d s ««ith e l o n g a t i o n of 
the alkyl chain on the N-atom. 
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from the literature discussed before,it may be assum­
ed that the gradual decrease in the activity as dem­
onstrated in fig. 3-3 and 3-4 has to be ascribed 
mainly to a gradual decrease in the intrinsic activ­
ity, although as may be seen from the shift in the 
curves the affinity also varies. If the "inactive" 
compounds such as N-secbutylphenylarterenol (Me 18) 
and N-secbutylphenylsympatol (Ma 19) lost their in­
trinsic activity but kept the affinity to the specific 
receptors they may be expected to behave as competi­
tive antagonists with respect to arterenol. The answer 
may be obtained from concentration-response curves 
for arterenol in the presence of constant concentra­
tions of these "inactive" compounds. Fig. 3-5a and 
3-5b give experimental results. 
% contraction 
100 
КГ
1
 1 
mu Arterenol 
т м Arterenol 
3 - 5 , а - Ь C u m u l a t i v e l o g c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r a r t e r e n o l 
i n t h e p r e s e n c e o f c o n s t a n t c o n c e n t r a t i o n s o f Mc 18 ( f i g . 
3 - 5 a ) a n d Ma 19 ( f i g . 3 - 5 b l t e s t e d o n t h e v a s d e f e r e n s o f 
t h e r a t . 
N o t e t h e p a r a l l e l s h i f t o f t h e c u r v e s i n d i c a t i n g a c o m p e t i ­
t i o n . 
The parallel shift in the curves for arterenol allows 
the conclusion to be drawn that Mc 18 and Ma 19 real­
ly act as competitive antagonists. Compare fig. 3-5a 
and 3-5b with fig. 2-2. 
If the effect of a certain agonist is antagonized 
in a competitive way by various antagonists, these 
antagonists interact with the same receptor system, 
viz. that on which the agonist induces its effect. 
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If a certain antagonist inhibits the effects of var­
ious agonists in a competitive way and the pA2 values 
obtained with that antagonist, in regard to the var­
ious agonists, is the same, then these agonists inter­
act with a common receptor system (24). With this in 
mind we tested the inhibitive action of N-isobutyl-
phenylarterenol (Mc 5) with respect to N-ethylarter-
enol and arterenol. As is demonstrated by fig. 6a and 
6b, a certain concentration of Mc 5 results in iden­
tical shifts for both agonistic compounds. 
% contraction -
100-
тм N-Et Arterenol m M Arterenol 
F i д . 3 - 6 > а - Ь C u m u l a t i v e l o g c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r N - E t - a r t e r -
e n o l ( 6 a l a n d a r t e r e n o l l 6 b ) i n t h e p r e s e n c e o f c o n s t a n t 
c o n c e n t r a t i o n s o f Mc 5-
N o t e t h e p a r a l l e l s h i f t o f t h e c u r v e s . C o n s t a n t c o n c e n t r a ­
t i o n s o f M c 5 r e s u l t i η an e q u a I s h i f t o f t h e c u r v e s i r r e s p e c -
t i ve o f t h e a g o n i s t u s e d * 
The pA2 value for Mc 5 with arterenol is found to be 
5.5) with N-ethylarterenol it is found to be 5.4. 
It may happen that a certain antagonistic compound 
inhibits two agonistic compounds in a competitive 
way, whereas both agonistic compounds interact with 
different specific receptors. This is the case with 
certain dioxolane derivatives with respect to dil-
vasène and histamine, tested on the isolated gut of 
the guinea pig. In that case, however, the pA2 values 
are found to be different (25). 
The gradual change from agonist to competitive 
antagonist as demonstrated in fig. 3-3 and 3-4 may 
be ascribed to a gradual decrease in the intrinsic 
activity as a result of the gradual increase in the 
substituent on the nitrogen atom in both series of 
compounds. 
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This means that the partial agonists N-ethyl-, N-
propyl- and N-isopropylarterenol and N-propyl- and 
N-isobutylsympatol are expected to behave as compounds 
with an intermediate intrinsic activity. 
Experimental proof of this may be obtained by pro­
ducing concentpation-response curves for arterenol 
in the presence of various concentrations of a partial 
agonist. Fig. 3-7a represents such an experiment, viz. 
N-isopropylarterenol combined with arterenol. 
(Jfr 
N-iPrArt 0 5 10 20 т м 
I1JJ 
IO"3 IO" 2 IO"1 1 IO" 2 IO' 1 1 
mu Arterenol т м Arterenol 
F i g . 3 - 7 , a - b C u m u l a t i v e l o j c o n c e n t r a t i o n - r e s p o n se c u r v e s f o r a r t e r e n o l 
i n t h e p r e s e n c e o f c o n s t a n t c o n c e n t r a t i o n s o f Ν - i P r - a r t e r e n -
o l i t e s t e d o n t h e vas d e f e r e n s o f d i f f e r e n t r a t s . 
N o t e t h e a g o n i s t i c П а ) and t h e c o m p e t i t i v e a n d n o n - c o m p e t i t ­
i v e a n t a g o n i s t i c p r o p e r t i e s o f N - i Ρ г - а r t e r e n o I . 
A comparison of the concentration-response curves 
obtained with those represented in fig. 2-3 shows 
that theory and experiment agree. 
With other partial agonists analogous results were 
obtained. The partial agonists behave as compounds 
with intermediate intrinsic activities. 
As mentioned in chapter 2 paragraph 2.5 the pD2, 
pA2 and p D ^ values are a measure for the affinity of 
the various drugs, agonists and antagonists, to their 
specific receptors. Table (З-і) and table (3-2) rep­
resent these values for both series of compounds 
under discussion. In the tables the intrinsic activ­
ities in relation to that of -/-arterenol, which is 
taken as a unity, are also given. 
l O O n 
eo 
60-
40 
204 
N-iPrArt 0 10 
Г 
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T a b l e 3-1 I n t r i n s i c a c t i v i t i e s and a f f i n i t i e s ( e x p r e s s e d as pD2» pAo and 
ρϋ*2 v a l u e s ) of d e r i v a t i v e s of a r t e r e n o l tested on the isolated 
vas d e f e r e n s of the rat. 
./-arterenol 
^-N-meart. 
N-etart. 
N-isopropart. 
N-propart. 
N-isobutart. 
N-butart. 
N-1,1 - 2 , 2 tetraoie-
propart. 
N-"isobutphen"art. 
N-"isopropphen"art, 
N-"secbutphen"art. 
(Cc 16) 
M^c 50) 
.(Mc 21) 
(Mc 18) 
н о - < ) - с - с -
в = 
H 
с 
с-с 
с 
с 
о-с-с 
с 
¿-С 
\ 
с 
с-с-с-с 
с с 
/ / 
С-С-С \ \ 
с с 
о 
до 
С — 
с-с-с/ 
i 
α 
1 
1 
0.9 
0.4+ + 
0.3 
\ 
-N-R 
.а. 
/О/О· 
0 
) о 
-1 
-1 
0 -1 
0 
0 
0 
pD2
+) 
5.2(0.1) 
5.6(0.2) 
4.7(0.2) 
4.5 
3.3 
РА2
+) 
2.5 
3.6 
5.5(0.3) 
5.0(0.3) 
5.2(0.2) 
ρϋ·2+) 
2.1 
2.0 
2.8 
N-"dimebutphen"art. (Cc 42) О-С-С-С·/ } 0 5.1(0.3) 
С 
+ ) The 95% confidence value of the mean affinity is obtained by adding and 
substracting from the given numbers the value between the parenthesis. 
+ + ) In a nuD'ber of experiments no contraction was obtained with N-isoprop­
art. Under these circumstances the compound behaves as a competitive 
antagonist of art. (fig. 3-7b). 
For N-isopropart. α varied from 0-0.6. 
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The given numbers are the average values of the 
af f inities, pD2,pA2 and p D ^ (see chapter 2, paragraph 
2-5) obtained from minimum six experiments. 
The extreme values of the experimental results 
differed 0.3-0.4 in table 3-1 and 0.2-0.4 in table 
3-2 of the average values. 
The pD2 values are the negative logarithms for the 
average values of the molar concentration of the 
various agonists which give a 50^ response. So for 
arterenol we found (fig. 3-2a) as a average molar 
concentration 64.10~' which results in a pD2 value of 
5.2. 
The pA2 values are the averages of the рАз values 
calculated with the help of eq. 2-9 in which χ is the 
concentration-tract over which the concentration-
response curve of the agonist, arterenol, is shifted 
as a result of the presence of the competitive antag­
onist and pA
x
 the negative logarithm of the molar 
concentration of the antagonist concerned. See, for 
instance fig. 3-5· 
The pD'2 values are the negative logarithms for 
the average values of the molar concentrations of the 
non-competitive antagonists which reduce the maximal 
height of the curves for the agonist, arterenol, to 
50%. See fig. 3-9. 
From these tables it can be seen that the gradual 
increase of the substituents leads to a gradual de­
crease in the pDo values, while for the aralkyl com­
pounds as Mc 5i Mc 21, etc. and Ma 20, Ma 19, etc. 
again rather high values for the pA2 values are found. 
This means that starting with highly active mimetics 
the series ends with highly active lytics, but between 
these two extremities compounds with lower affinities 
are found. 
Since the optical isomers of arterenol differ in 
their activity (fig. 3-8a) it may be concluded that 
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T a b l e 3~2 I n t r i n s i c a c t i v i t i e s and a f f i n i t i e s ( e x p r e s s e d as pD^* pA2 and 
p O ' 2 v a l u e s ) o f d e r i v a t i v e s o f n o r s y m p a t o l t e s t e d on t h e i s o l a t e d 
vas d e f e r e n s o f t h e r a t . 
HO-( V¿-C-N-R 
^ ^ R» 
i. a. pD2+) pAj*) pD2'+) 
11·= R= α ββ' 
Norsympatol (N-symp) Η Η 1 4.6(0.2) 
N-mesymp HC 1 4.1 
N-propsymp H C-C-C 0.5 3.0 
С / 
N-isobutsymp Η C-C 0.2 2.5 
С 
N-butsymp Η C-C-C-C -ι 2.4 
N-isobutphensymp (Ma 20) Η C-C-/ \ 0 5.6(0.3) 
ч
с ^—' 
N-secbutphensymp (Ma 19) Η C-C-C-/ \ 0 5.5(0.2) 
Duvadilan С C-C-0-( > 0-1 6.0(0.3) 4.2 
Nylidrinum С C-C-C-/ > 0 6.2(0.3) 
+) The 95% confidence value of the mean affinity is obtained by adding and 
subetractlng from the given numbers the value between the parenthesis. 
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arterenol must fit rather closely to the specific 
receptors. This means that change in the structure 
of the compound will, as a rule, result in a less close 
fit of the drug and receptor and therefore in a de­
crease in both the affinity and the intrinsic activ­
ity or one of the two. The smaller the molecules of 
the drug, the larger will be the change that both are 
changed at the same time. If the chemical structure 
of N-aralkyl substituted derivatives, e.g. Mc 5 and 
Ma 20, are compared with that of arterenol, it will 
become probably that the receptor surface with which 
the lytics interact, will be larger than that for the 
mimetics. Long (26) concluded from experiments with 
various cholinolyticsthat introduction of flat groups 
gives a higher activity. This is also the case with 
the introduction of the planar phenyl ring in the 
N-substituted arterenol derivatives. 
% contraction • 
100 
0 0 -
6 0 
4 0 
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10' гЗ 10 -2 IO"' 
т м Arterenol 
F i g . 3 - 8 а C u m u l a t i v e l o g c o n c e n t r a t i o n - r e s p o n s e c u r v e s іот4-і<і£- and>tí¿-
a r t e r e n o t t e s t e d on t h e v a s d e f e r e n s o f t h e r a t . 
N o t e t h e v a r i a t i o n i n t h e a f f i n i t y o f t h e i s o m e r s . 
Probably the planar phenyl ring in the aralkyl group 
contributes to extra binding forces of the lytic to 
its receptor. In other words with the introduction 
of the aralkyl group the receptor for the drug is 
extended, which results in additive binding forces 
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and therefore in an increase in the affinity. In 
these sympatholytics the structural requirements that 
are essential for the original mimetics, in this 
case arterenol and sympatol, are of less importance, 
probably because a good part of the binding forces 
is now obtained from a different part in the molecule, 
not present in the mimetics. The difference in af­
finity, pA2 and pD2 values, between catechols and sym-
patols is smaller for lytics than for mimetics (see 
table 3-1 and 3-2). 
β ¿» - и -
art >10" 4 i lO" 4 xlO-· x l O - 4 ч 1 0 " 4 т м 
Сс25 'вк1(Г г Cc25 J8x IO"2 т м 
F i g . 3-8t> C u m u l a t i v e l o g c o n c e r t r a t i o n - r e s p o n se c u r v e s as r e g i s t e r e d o n 
t h e s o o t e d d r u m f o r a r t e r e n o l a l o n e a n d i n t h e p r e s e n c e o f • & -
Cc 25 and,C¿-Cc 25 r e s p e c t i v e l y . 
N o t e t h e d i f f e r e n c e i n a f f i n i t y o f t h e i s o m e r s . 
Especially interestins in this respect is the com-
parison of the sympatholytic aralkyl substituted deriv-
atives , viz. ./-Cc 25 and-¿-Cc 25 obtained from -<f- and 
¿i-arterenol respectively. Compound /-Cc 25 is obtain-
ed by introduction of ap-hydroxyphenylisopropyl group 
in -/-arterenol and ¿-Cc 25 by introduction of the same 
group in ¿-arterenol.Whereas -/-arterenol has a higher 
affinity than ¿-arterenol, see fig. 3-8a, the compound 
/-Cc 25, obtained f rom /-arterenol, is less active as 
a sympatholytic than the compound obtained from ¿-ar-
terenol, i.e. the reversed situation. 
Fig. 3-8b shows an original registrogram for combin-
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ations of /-arterenol with the two lytics just men­
tioned. This again shows that in these sympatholytics 
the configuration of the arterenol side chain is less 
important asfar as affinity of the lyticsis concern­
ed. 
The alkyl substituent derivatives of arterenol and 
nor-sympatol with a larger number (З-^) of carbon 
atoms in the substutuent have only a very small af­
finity to the specific receptors.The complementarity 
between the molecular structure of arterenol and its 
specific receptor is disturbed and therefore the 
binding forces decrease and the affinity also de­
creases. 
On the other hand these N-substituted derivatives have 
something in common with papaverine-like compounds, 
many of which are secondary and tertiary amines, see 
the structural formulae of papaverine and sestron. 
A compound rather similar to papaverine and sestron 
is for instance Caa 12. 
OH 
ι 
C j ^C C<AJL^N HO-kJ
 c
,N 
С C-C χ c c 
ϊ O- i ó «* V 
sestron papaverine Caa 12 
Fig. 3-9a and 3-9Ъ represent concentration-response 
curvee of arterenol in the presence of constant con­
centrations of Caa 12 and papaverine respectively. 
Both compounds exhibit a non-competitive antagonistic 
action. The pD'2 values of Caa 12 and papaverine are 
4.5 and 4.7 respectively, compare with table 3-1 and 
3-2 especially with the p D ^ value of duvadilan.Com­
pare the experimental concentration-response curves 
of fig. 3-9 with the theoretical concentration-res­
ponse curves of fig. 2-4. 
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That the compound Caa 12 haa a rather strong papaver-
ine-like action is in accordance with the conclusion 
of Kralt (27) that the ionyl group present in this 
molecule is preferred for this type of action. 
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Whether the N-alkyl substituted derivatives behave 
mainly as competitive, as non-competitive, or as mul­
tiple competitive and non-competitive antagonists, 
depends on the relation between pA2 and pD'g values. 
From table 3-1 and 3-2 it may be seen that N-isobutyl-
arterenol and N-butylarterenol mainly behave as non­
competitive antagonists ;compoundN-l, 1-2 ,2 tetramethyl-
propylarterenol (Cc 16) behaves as a multiple antag­
onist (fig. 3-10).Also in the case of compounds which 
are practically pure competitive antagonists, such as 
duvadilan, if sufficiently high concentrations are 
applied, a non-competitive component in the antagon­
istic action appears, see fig. 3-11. 
The partial agonists, if applied in higher doses, also 
reveal a non-competitive component in their action. 
Although the compound N-isopropylarterenol often 
caused a contraction of the vas deferens of the rat, 
in a number of cases no contraction was obtained, so 
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the compound behaved as if its intrinsic activity 
were zero. In the concentration-response curves obtain­
ed with these organs for arterenol in the presence of 
N-isopropylarterenol, the latter exhibits a dualism in 
antagonism. It behaves as a competitive antagonist, 
on which in higher concentrations a non-competitive 
antagonism is superimposed (see fig. 3-7Ъ and compare 
with fig. 2-5). 
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To sum up: in the series of N-alkyl and N-aralkyl 
substituted arterenol and nor-sympatol derivatives 
there is a gradual change from agonistic to compet­
itive antagonistic compounds with, in transition, 
compounds with an intermediate intrinsic activity, 
partial agonists, and compounds that mainly behave 
as non-competitive antagonists or multiple antagon­
ists. This rather complicated situation may be reason­
ably interpreted on the basis of the gradual de­
crease in the complementarity between the drugs and 
the specific receptors which is conducted by a gradual 
decrease of the affinity and the intrinsic activity 
and a gradual extension of the receptor surface for 
the drugs as a result of the introduction, especially 
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of the aralkyl group, with again an increase of the 
binding forces and the affinity. 
The study of the series of arterenol and nor-sym-
patol derivatives revealed two important points: 
1. the gradual change from mimetics to lytics or from 
agonists to their competitive antagonists may be 
attributed to a gradual decrease in the intrinsic 
activity. 
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2. Although a relationship in the chemical structures 
of mimetics and lytics is evident, the receptor 
surfaces of the lytics need not be fully identical 
with those for the mimetics. 
As a rule the molecules of the lytics are more ex­
tensive than those of the mimetics. See table 3-1 and 
3-2.This means that very probably the receptor surf­
aces with which they interact will also be more ex­
tensive. The receptor surface of the lytic may be only 
partially identical with that of the mimetic. It is 
even possible that the lytic interacts with a receptor 
surface different from that of the mimetic, but loc­
ated so close to it that the receptor of the mimetic 
is nevertheless functionally blocked (28). 
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Of the various sympatholytics mentioned in 3.2.3, 
a number was tested for their antagonistic properties 
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c o m p e t i t i v e a n t a g o n i s m . 
with respect to arterenol. Fig. 3-12a and 3-12b re­
present some of the experimental results. There is 
a clearly competitive relationship. 
3.2.7 A d r e n e r g i c r e c e p t o r s . 
As already stated adrenaline exerts opposite ef­
fects on various organs, viz. excitatory and inhibit­
ory actions. The first who tried to explain this was 
Dale (29). He differentiated two distinct types of 
receptors. Adrenaline acting on receptors which in­
duced an excitatory effect could be antagonized by 
ergot alkaloids,while adrenaline acting on receptors 
which induced an inhibitory effect, could not be antag­
onized by ergot alkaloids. There was one exception, 
namely the excitatory action of adrenaline on the 
mammalian heart was not antagonized by ergot alkal­
oids. This is also the case for the different natural 
and synthetic adrenergic blocking agents developed 
afterwards (30). Ahlquist (3I) classified adrenergic 
receptors in different effectors based on the order 
of potency of a series of six sympathomimetic amines. 
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He differentiated between a- and /^-receptors. The 
order of potency of three of the most important sym­
pathetic substances on α-receptors is: adrenaline 
karterend » N-isopropylarterenol. Those on /}-re­
ceptors is N-isopropylarterenol » adrenaline > arter-
enol. 
After occupation of most of the a-receptors an ex­
citatory responae occura and after occupation of moat 
of the /3-receptors an inhibition response occurs. 
There are, however, two important exceptions: 
1. though the intestines produce an inhibitory effect 
under influence of sympathetic substances, the 
order of potency is adrenaline > arterenol » N-
isopropylarterenol.So the adrenergic receptors of 
the intestine are α-receptors. 
2. though the heart action is stimulated under in­
fluence of sympathetic substances, the order of 
potency is N- isopropylarterenol » adrenaline > 
arterenol. So the adrenergic receptors of the 
heart are /Ö-receptors. 
Ahlquist's classification (Зі) is supported by 
the fact that most of the responses mediated through 
α-receptors could be blocked, the response mediated 
through /j-receptors could not be blocked by adren­
ergic blocking agents (32). 
Lands (33) made also a differentiation in adren­
ergic receptors and classified them according to the 
effects independent of the order of potency of the 
mimetics. This, because according to Lands (34) the 
order of potency of the substances used by Ahlquist 
differed considerably with the species of animal and 
the experimental conditions employed. 
The discussion about the adrenergic receptors is 
still going on (35» З6, 37, 38). Under the influence 
of the work by Cannon and Bosenblueth (39) the effects 
obtained after the occupation of the adrenergic re­
ceptors are often stressed (35, 40, 4l). This is a 
wrong interpretation of the idea of receptor. 
We must remember that the term receptor only makes 
sense in connection with drugs which interact with 
the receptors. A receptor, as originally stated by 
Langley (42) is a "receptive substance" with which a 
pharmacon interacts, so it is the place in the bio­
logical object "receiving" the drug. The effects of 
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the object are secondary. It ia not correct to 
classify receptors according to the effects which are 
induced after occupation of them. Receptors must be 
classified according to the substances with which the 
receptors interact. 
Principally this has been done by Ahlquist (31) in 
the case of mimetics and supported by Konzett (32) 
with the sympatholytics. So Ahlquist's a- and /3-re­
ceptor theory remains a useful approximation. 
The α-receptors are those adrenergic receptors 
which after occupation by sympathomimetics give an 
effect which can be antagonized with classical sym­
patholytics. These are called α-sympatholytics. 
The /J-receptors are those adrenergic receptors 
which after occupation by a sympathomimetic give гш 
effect, which cannot be antagonized with classical 
sympatholytics. It is possible that a sympathomimetic 
can occupy both the a- and the /^-receptor, as in the 
case of adrenaline. Adrenaline acts as an α-sympath­
omimetic as well as a yö-sympathomimetic. As already 
seen N-isopropylarterenol can also act as an α-sym­
pathomimetic and as an α-sympatholytic, but it acts 
mainly as a /з-symnathomimetic. It gives a bronchodi­
latation and acts stimulatingly on the heart. These 
effects cannot be antagonized by the classical symp­
atholytics. 
A substance has recently been found,the dichloro-
analog of N-isopropylarterenol, which antagonizes 
the broncho-dilating effect, the vasodilatation and 
the tachycardia, caused by N-isopropylarterenol (^ З)· 
The substance has little effect on c-receptors (Зв), 
so it probably acts as a/j-lytic. After discussing 
the actions of this substance Slater and Powell (38) 
concluded that the dichloro-analog of N-isopropyl­
arterenol "can be considered as a useful tool for the 
qualitative separation of a- and /3-receptor sites, 
but for the present it must be used with caution for 
the quantitative aspects are not clear". 
In our experiments with the vas deferens of the 
rat, arterenol, adrenaline and N-isopropylarterenol, 
cause a contraction which can be antagonized by sev­
eral classical sympatholytics, so according to Ahl­
quist the organ must contain α-receptors.The dichloro-
analog of N-isopropylarterenol behaves as papaverine, 
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so as a non-competitive antagonist (fig. 3-13, com­
pare with fig. 2-4). 
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As mentioned before there is a clear relationship 
between ACh and its competitive antagonist, atrop­
ine. In these lytic there is a heavy substitution 
at both sides of the molecule on the nitrogen atom 
and on the negative side of the molecule, namely in 
the acid used in the esterification of the amino-
alcohol. 
We shall turn our attention especially to the last 
type of substitution. The question arises as to what 
course the gradual change from agonists, parasympath­
omimetics, to competitive antagonists, parasympath­
olytics takes in a series of derivatives of ACh. 
Uow do the compounds behave in the transition from 
mimetics to lytics? 
m M Arterenol 
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The series of compounds to be studied has the follow-
ing general formula: 
/c 
R-Ç-0-C-C-N+-C 
ό
 N
c 
in which R .may be hydrogen, alkyl or aralkyl group. 
The various derivatives will be mentioned as acetyl 
(ACh)-, propionyl- (PropCh), etc. choline. 
3.3·1 L i t e r a t u r e s u r v e y . 
Although there is a large body of experimental 
data available on the relationship between structure 
and activity of various choline esters, the question 
mentioned above has not yet been answered. Within the 
frame of this thesis it is not possible to review in 
detail all data on the choline esters. Those points 
which are of direct interest to our problem will be 
discussed more extensively. 
A number of reviews covers most of the data (3, 6, 44). 
As already stated we must differentiate between 
various types of action for ACh: 
1. the muscarinic type, due to a direct action on the 
receptors for ACh at the parasympathetic end-
synaps. 
2. The nicotinic action, due to the action on the re­
ceptors at the interneuronal synapses in the gang­
lia of both sympathetic and parasympathetic nerves. 
The muscarinic type of action can be antagonized 
by atropine. The ganglionic stimulating nicotinic 
action of ACh becomes visible, for instance, as an in­
crease in the blood-pressure with higher doses of ACh 
after atropinization of the animal. The nicotinic 
action is only antagonized to a certain degree by 
atropine; it is, however, antagonized by ganglionic 
blocking agents, such as hexamethonium. 
This indicates a difference in the receptors for ACh 
at both synapses. In a study on the variation of the 
structure of choline esters, these differences may 
be involved and make the relationship more complicat­
ed. 
Much of the previous work with choline esters is 
concerned with the blood pressure of the cat (45) and 
the dog (46). These experiments show that with an in-
crease of the number of carbon atoms in the acyl por-
tion of the esters, the depressor action of ACh de-
creases and changes into a pressor effect. 
This makes it probable that, as a result of the change 
in the structure, the muscarinic, parasympathomimetic 
action disappears or possibly makes way for a para-
sympatholytic action while the nicotinic action re-
mains or even becomes stronger.Experiments with isol-
ated organs, especially with the isolated guinea pig 
intestine, also reveal the appearance of nicotinic 
action in the higher esters of choline (44, 47). 
In order to avoid these difficulties it will be 
suitable to use an organ in which only one of the two 
types of action, the muscarinic or the nicotinic, can 
be realized. The isolated intestine of the guinea 
pig, used in the study on the relationship between 
structure and activity by Schneider and Timms (44) 
and Lehr (4?), is not very suitable because it has a 
muscarinic as well as a nicotinic response. 
The authors mentioned carried out their experiments 
with the guinea pig intestine in the presence of a 
certain concentration of hexamethonium in order to 
eliminate the nicotinic type of action. 
Such a procedure, however,has its pitfalls. The antag-
onistic relationship between hexamethonium and a chol-
ine ester as a nicotinic drug is of a competitive type 
or the antagonism is at least surmountable. This means 
that a certain dose of hexamethonium sufficient to 
suppress the nicotinic action of a certain dose of a 
choline ester, may be insufficient for higher doses. 
As we are planning to make concentration-response 
curves for the various esters and possibly to shift 
these concentration-response curves to higher concen-
trations with the aid of their competitive antag-
onists, it will be clear that rather high doses of 
hexamethonium would then be necessary. 
On the other hand high doses of hexamethonium them-
selves also reveal parasympatholytic activity besides 
the ganglionic blocking action (25). 
The isolated jejunum of the rat responds to nicotine 
hardly or not at all, at least certainly not in doses 
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to which the isolated intestine of the guinea pig 
responds. 
For this reason it is of advantage to use the isolated 
gut of the rat, as our investigation concerns un anal­
ysis of the gradual change from parasympathomimetic 
to parasympatholytic properties in a series of chol­
ine esters. Fig. 14a and Ikb demonstrate some of the 
differences between the isolated jejunum of the rat 
and guinea pig with respect to nicotine. 
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The antagonistic action of hexamethonium with respect 
to nicotine is demonstrated in fig. 14a. 
Although in the experiments of Schneider and Timms 
(44) and Lehr (4?) the change from parasympathomim­
etics to parasympatholytics in the series of choline 
esters is suggested, they do not refer in detail to 
the transition of one type of action to the other. 
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It is possible that compounds with, for example, 
intermediate intrinsic activities or a dual mode of 
action exist. In the following pages a series of ex­
periments will be described carried out on the isol­
ated jejunum of the rat with an emphasis on the con­
centration-response curves for the various compounds 
and their combinations. 
З.З.2 M e t h o d s a n d m a t e r i a l s . 
The rat jejunum is fairly insensitive to nicotine 
(see fig. l^ a and 14b). Therefore this object is 
suitable to test parasympathomimetics, because in this 
case the nicotinic properties of the drugs tested will 
not interfere with their parasympathetic properties. 
The jejunum was obtained from the animal in the 
usual way. Pieces of about 2 cm were suspended in a 
bath containing 10 ml Tyrode of 37° С and bubbled 
with air. The responses were registered on a sooted 
drum in an isotonic way with a lightly loaded lever. 
In all cases cumulative concentration-response curves 
were made with a dosage technique as described for 
the arterenol derivatives in paragraph 3.2.5. 
As ACh itself is less suitable to make cumulative 
concentration-response curves(the compound is easily 
hydrolysed), in most of our experiments we use the 
parasympathomimetic furmethonium (lIFur) as an agonist. 
If concentration-response curves for HFur obtained 
with different pieces of isolated jejunum are com­
pared, a variation in the pDo values will be found. 
The curves are "parallel" within close limits. 
If concentration-response curves obtained with one 
piece of jejunum are compared, the variation in pD2 
value will be found to be much smaller, see table 3-3· 
T a b l e 3 - 3 A f f i η i t y ( e i t p r e s s e d a s p D 2 v a l u e s ) o f Η F u r t e s t e d o n t h e i s o l a t e d 
j e j u n u m o f t h e r a t . 
PD2 P95 
8 rats 6.2 5 . 9 - 6 . 4 
1 rat 6.1 6.0 - 6. 2 
3 . 3 - 3 E x p e r i m e n t s . 
As a l r e a d y s t a t e d , f o r an a n a l y s i s of t h e r e l a t i o n ­
s h i p between chemica l s t r u c t u r e and a c t i v i t y , c o n ­
c e n t r a t i o n - r e s p o n s e c u r v e s are e s s e n t i a l . 
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Fig. 3-15 represents cumulative log concentration-
rosponse curves for a series of choline esters. 
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From these concentration-response curves we can see 
that with an increase of the number of carbon atoms 
of the acyl group, there is a gradual change from 
active compounds to "inactive" ones. On the basis of 
the theory and data from the literature discussed 
above, it may be assumed that this gradual change in 
the activity has to be ascribed mainly to a gradual 
decrease in the intrinsic activity, although as may 
be seen from the shift in the curves the affinity also 
varies. If the "inactive" compounds such as capron-
ylcholine (HexaCh) and laurylcholine (DodecaCh) lose 
their intrinsic activity, but keep their affinity to 
the specific receptors, they may be expected to be­
have as competitive antagonists with respect to ACh 
and other parasympathomimetics such as IIFur. 
The fact that atropine, which is known to be a com­
petitive antagonist for ACh, gives identical pA2 val­
ues for ACh, IIFur and PropCh, if tested on the isol­
ated gut of the rat, allows the conclusion to be 
drawn that IIFur and PropCh respectively interact with 
the same specific receptors as ACh (fig. l6a and l6b) . 
For atropine in combination with ACh a pA2 value of 
9.2, in combination with lIFur a pA2 value of 9.4 and 
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( l o a ) i n t h e p r e s e n c e o f c o n s t a n t c o n c e n t r a t i o n s o f a t r o ^ i n e 
t e s t e d on t h e r a t j e j u n u m . 
b . C u m u l a t i v e l o g c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r p r o p -
i o n y l c h o l i n e i n t h e p r e s e n c e o f c o n s t a n t c o n c e n t r a t i o n s o f 
a t r o p i n e ! t e s t e d on t h e r a t j e j u n u m . 
N o t e t h e p a r a l l e l s h i f t o f t h e c u r v e s . C o n s t a n t c o n c e n t r a -
t i o n s o f a t r o p i n e r e s u l t s i n an e q u a l s h i f t o f t h e c u r v e s 
i r r e s p e c t i v e o f t h e a g o n i s t u s e d . 
% contraction 
100 τ 
0 0 
6 0 
4 0 
2 0 
Hexa Ch 0 6 32.10"*тм DodecaChO 
10" 10 -3 IO'2 
т м H Fur m м HFur 
F i g . 3 - 1 7 , а - Ь C u m u l a t i v e l o g c o n c e n t r a t i o n - r e s p o n se c u r v e s f o r H F u r i n 
t h e p r e s e n c e o f c o n s t a n t c o n c e n t r a t i o n s o f H e x a C h ( 1 7 a J a n d 
D o d e c a C h ( 1 7 b ) t e s t e d o n t h e r a t j e j u n u m . 
N o t e t h e p a r a l l e l s h i f t o f t h e c u r v e s f o r t h e a g o n i s t , i n ­
d i c a t i n g a c o m p e t i t i o n . 
in combination with PropCh a pA2 value of 9.1 was 
found, thus HFur may be used as a parasympathomimetic 
instead of ACh to t e s t the "inactive" compounds 
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mentioned above as to their possible competitive antag­
onistic action. 
For this purpose concentration-response curves for 
HFur in the presence of constant concentrations of 
HexaCh and DodecaCh were made. Fig. 17a and 17b give 
the experimental results. The parallel shift in the 
curves for UFur allows us to conclude that IlexaCh and 
DodecaCh act as competitive antagonists, therefore as 
parasympatholytics. Compare fig. 17a and 17b with the 
theoretical curves represented in fig. 2-2. 
The gradual change from agonist to competitive 
antagonist as demonstrated in fig. 3-15 may be ascrib­
ed to a gradual decrease in the intrinsic activity 
as a result of a gradual increase of the number of 
carbon atoms in the acyl group in the various choline 
esters. 
% contraction 1 
100 
60 
6 0 
40 
2 0 -
\0'4 10"1 10"2 10"' 
т м H Fur 
F i g . 3 - 1 8 C u m u l a t i v e l o g c o n e e n t r a t i o n - r e s p o n se c u r v e s f o r H F u r i n t h e 
p r e s e n c e o f c o n s t an t c o n c e n t r a t Î on s o f bu t y г y I с ho I i ne , t e s t e d o n 
t h e r a t j e j u n u m . 
N o t e t h e a g o n i s t i c a n d c o m p e t i t i v e a n t a g o n i s t i c p r o p e r t i e s o f 
b u t y r y l c h o l i n e . 
This means that the partial agonists such as ButCh and 
iButCh are expected to behave as compounds with an 
intermediate intrinsic activity. 
Experimental proof of this may be obtained by produc­
ing concentration-response curves for HFur in the 
presence of constant concentrations of the partial 
agonists. 
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f/T 
Butyrylcholine 0 U 2j6 т м 
Fig. 3-18 represents such an experiment, viz. ButCh 
with HFur. A comparison of the concentration-response 
curves obtained with theoretical curves represented 
in fig. 2-3 shows that theory and experiment agree. 
With iButCh analogous results were obtained. The part­
ial agonists behave as compounds with intermediate 
intrinsic activity. 
As mentioned in chapter 2, paragraph 2-5 the pD2, pA2 
and p D ^ values are a measure for the affinity of the 
various drugs,agonists and antagonists,to their spec­
ific receptors. Table 3-^ represents pD2 and pA2 
values for the series of choline esters under dis­
cussion. In the same table the intrinsic activities 
in relation to IIFur, which is taken as a unity, are 
also given. From this table it may be seen that a 
T a o l e З - 1 * I n t r i n s i c a c t i v i t i e s a n d a f f i n i t i e s ( e x p r e s s e d as p D ^ a n d p A 2 
v a l u e s ) o f c h o I i n e - e s t e r s t e s t e d on t h e i s o l a t e d j e j u n u m o f t h e 
r a t . 
/C 
R-C-0-C-C-N+-C 
H s 
О С 
R= i . a. p D 2
+ ) pA 2 + ) 
FormCh. H- 1 5.2(0.2) 
AcetCh. C- 1 7.6 
PropCh. C-C- 0.9 5.0(0.3) 
Q 
IsobutCh. XC 0.4 4.1 
С 
ButCh. O-C-C- 0.3 3.8 
Q 
IsopentCh. чС-0- 0 3.9 
С 
HexaCh. С- 0 4.0 
DodecaCh. Clì 0 5.3(0.2) 
TetradodecaCh. С,. 0 5.5(0.2) 
(Diphenoxyacet)metCh. (Lachesine; 0 8.4 
HFur С — С „ 
Il II ^ c 
С C-C-N+-C 1 6.2 V "с 
+) The given numbers are average values of the affinities obtained 
from minimum 6 experiments, the extreme values of the experimental 
results differed 0.3 - 0.4 of the average values. The 95% con­
fidence value of the mean affinity is obtained by adding and 
substracting from the given numbers the value between the 
parenthesis. 
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gradual increase in the number of carbon atoms leads 
to a gradual decrease in the pD2 values, while for a 
larger number of carbon atoms, such as HexaCh and 
DodecaCh an increase in the pA2 values again takes 
place.The introduction of phenyl substituted carbonic 
acids such as in lachesine (fig. 3-19) results in a 
strong increase in the pA2 value. 
% contraction 1 
100-
8 0 -
6 0 -
4 0 -
2 0 -
10" 4 I O - 3 IO" 2 IO"1 
т м H Fur 
F i g . 3 - 1 9 C u m u l a t i v e l o g c o n c e n t r a t i o n - r e s p o n se c u r v e s f o r H F u r ¡π t h e 
p r e s e n c e o f c o n s t a n t c o n c e n t r a t i o n s o f l a c h e s i n e t e s t e d o n t h e 
r a t j e j u n u m . , 
N o t e t h e p a r a l l e l s h i f t o f t h e c u r v e s f o r t h e a g o n i s t , w h i c h 
i n d i c a t e s a c o m p e t i t i v e a n t a g o n i s m . 
As far as the ACh-mimetics are concerned, there 
is an optimum for ACh, which is more active than Form-
Ch. Starting with highly active mimetics, the series 
ends with highly active lytics. Compounds with lower 
affinities to the specific receptors are found inter­
mediately. ACh isa highly active compound,which prob­
ably fits rather closely to its specific receptors. 
This is stressed by the fact that for the closely 
related compound /i-methylcholine there is a strong 
difference in activity for both optical isomers (48). 
There is a high degree of complementarity between 
these mimetics and their specific receptors, in such 
a way that changes in the structure of these compounds 
result as a rule in a less close fit of drug and 
receptor, therefore in a decrease in both the affinity 
and the intrinsic activity, or the latter only. 
Lachesine О 1 4.10"тпм 
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The smaller the molecule of the drug, the greater the 
chance that both will be changed at the same time. If 
the chemical structure of the parasympatholytic com­
pounds such as DodecaCh, lachesine, atropine, etc. 
is compared with that of ACh and IIFur, it will become 
probably that the receptor surface with which these 
lytics interact, will be larger than that for the mim-
etics. The planar phenyl rings especially may con­
tribute to the binding forces of the lytics to their 
receptors. In other words, with the introduction of 
the phenyl group at a certain distance from the ester 
grouping or from the quaternary ammonium group, the 
receptor for the drug is extended, which results in 
additive binding forces, and therefore in an increase 
in the affinity. 
T a b l e 3 " 5 I n t r i n s i c a c t i v i t i e s a n d a f f i n i t i e s ( e x p r e s s e d a s pD? - p A ? 
v a l u e s ) o f q u a t e r n a r y d i o x o l a n e s t e s t e d o n t h e r a t j e j u n u m ( 2 5 ) · 
0 _ C
 С 
RrJ I s 
С C-C-N+-C 
О С 
i.a. pDj РА2 
1 5.3 
1 4.3 
0.5 4.6 
0 4.4 
0 6.2 
С-С-С-С- 0 6.9 
В 1 =. 
с 
R 2 : 
H 
с 
C-C 
-C-C-
с * 
о-
7.1 
From this point of view, a study of phenylalkyl-
carbon acid esters, for instance the diphenylacetic 
acid ester of Л- and -/-/ö-methylcholine might be of 
interest. Possibly analogous to the situation found 
for ¿- and ^ -arterenol, in the corresponding lytics 
the original difference in activity for both optical 
isomers will be much less or absent. 
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From a study of a homologous series of dioxolane 
derivatives in which a gradual change from parasym-
pathomimetics to parasympatholytics also takes place 
(25), an analogous relationship between the chemical 
structure and the pD2 and pA2 values is found, see 
table 3-5. 
Here, too, there is a decrease in the pD2 values and 
an increase in the pA2 values, again with an increase 
in the substituent. 
The relationship demonstrated in table 3-1 and 3-2 
shows a similarity to the relationship found in table 
3-4 and 3-5· This time, however, on the transition 
from mimetics to lytics or for the derivatives with 
low pDg or pA2 values, therefore with a relatively 
low affinity, no papaverine-like action appears and 
the compounds do not behave like non-competitive antag-
onists. This is, probably, because we are dealing with 
quaternary ammonium compounds, while the papaverine-
like properties are restricted to tertiary and sec-
ondary amines. In the case of tertiary amines, how-
ever, a combinationof parasympatholytics and papaver-
ine-like activities is possible, as is demonstrated 
by the existence of multiple antagonists in this 
field such as adiphenine, propivan and avacan (49)· 
These compounds, however, are mainly competitive in 
their action as may be seen from table 3-6. 
Table 3~6 I n t r i n s i c a c t i v i t i e s and a f f i n i t i e s ( e x p r e s s e d as p A 2 and p D ^ 
values) of drugs with a du a l i s m in a n t a g o n i s m tested on the rat 
i Ieum 1491. 
Adiphenine 
Propivan 
Avacan 
ß 
0 
0 
0 
i . a . 
β' 
-1 
-1 
-1 
PA2 
6 . 8 5 
6 . 8 2 
6 . 8 9 
P D ' 2 
4 Л 
4 . 7 
4 . 7 
To sinn up: The study of a series of homologous 
choline esters revealed two important points: 
1. the gradual change from mimetics to lytics or from 
agonists to their competitive antagonists may be 
attributed to a gradual decrease in the intrinsic 
activity. 
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2. although the relationship in the chemical structure 
of mimetica and lytics is evident, the receptor surf­
ace of the lytics need not to be fully identical 
with that of the mimetics.As a rule the molecules of 
the lytics are more extensive than those of the 
mimetics, which means that very probably the re­
ceptor surface with which they interact will also 
be more extensive. 
3.4 S o m e g e n e r a l c o n s i d e r a ­
t i o n s o n t h e e x p e r i m e n t s 
c o n c e r n i n g a r t e r e n o l a n d 
a c e t y l c h o l i n e d e r i v a t i v e s . 
3.4.1 T h e s l o p e o f t h e c u r v e s . 
In the theory concerning drug-receptor interact­
ion a simple bimolecular equilibrium reaction was 
supposed to take place between drug and receptor. 
The slope of the experimental concentration-response 
curve, however, differs from that of the theoretical 
concentration-response curves as calculated from eq. 
2-4.The experimental curves are steeper, compare fig. 
2-2 with fig. 3-5 and 3-12. 
The disagreement between experiment and theory on 
this point brought a number of investigators to sup­
pose a higher order of reaction, for instance a tri-
molecular one (50). 
In that case the equilibrium should be written: 
R + nA tl^. RA
n 
R + шВ ÎZJ RB_ 
m 
Varying the value for η any desired slope of the curves 
can be obtained. In many cases the experimental 
curves have a slope for which η becomes a fraction. 
This is, however, meaningless with regard to the order 
of reaction. Possibly the differences between ex­
periment and theory with respect to the slope of the 
curves have to be ascribed to mechanical events in 
the contraction process of the isolated organ. 
In chapter 4 this problem will be discussed in more 
detail. 
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If concentration-response curves for competitive 
antagonists are studied using ρΑ
χ
 values - as follows 
from the definition of pA
x
 - the contraction state of 
the organ is a constant. 
This means that in that case an interference of mech­
anical events with the slope of the concentration-res­
ponse curves is improbable. 
For higher molecular reactions applies eq. 2-10: 
log U n - 1) = -log K B - ιηρΑχ (49) 
As mentioned in chapter 2 paragraph 2-5 a plot of log 
(x - l) against the pA
x
 value results in the case of 
the same order of reaction between the receptors and 
the agonist respectively the antagonist in a curve 
under a slope of 45°. 
log(x-l) 1 
2.0-1 
p A x 
Fig. 3-20 Curves obtained by plotting log tx-li versus pAy for various 
competitive antagonists of parasympathomimetics»sympathominietics 
and histamine. The broken lines are calculated from eq. 2-10 
for η = 1 and various values of m. 
Note that the experimental curves have a slope of H 5 0 which 
implies that the value n/m = 1 is well approached. 
In fig. 3-20 the experimental results obtained with 
a number of sympatholytics and parasympatholytics as 
antagonists of the corresponding mimetics are plot­
ted in the way just mentioned. From the curves thus 
obtained it may be seen that a value for n/m = 1 is 
well approached. 
3.4 .2 S p e c i f i c i t y o f t h e l y t i c s . 
On the basis of the theoretical considerations 
given in chapter 3-1> one might expect as a rule a 
clear relationship between the chemical structure of 
mimetics and the corresponding lytics. 
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The gradual change from agonist to competitive antag-
onist will occur if the chemical properties in the 
agonist that are essential for the intrinsic activ-
ity are lost, while the properties that are essential 
for the affinity are maintained. If we compare the 
chemical structures of sympathomimetics, for instance 
arterenol and adrenaline, with the various sympatho-
lytics, for most of these lytics it is hard to correl-
ate their chemical structure with that of the mimet-
ics. See formula in 3·2·3· The same obtains if the 
chemical structure of histamine is compared with that 
of various antihistaminics. 
The neurotransmitting substances dealt with in 
this thesis are amines or ammonium compounds. This 
makes it probable that on their receptor surface there 
is some negative site suitable to effect an ionic 
binding between the amino- or ammonium group of the 
mimetica and their receptors. If the various lytics 
for the neurotransmitters are compared, therefore 
ACh-lytics, antihistaminics, sympatholytics, etc. it 
will be found that all these compounds have some am-
ino or ammonium group in common, located at a certain 
distance, mostly 3-3 interatomic distances from some 
unsaturated ring configuratioiuSee following formulae. 
It is suggested that the amino or ammonium group 
interacts with the negative site on the specific re-
ceptors of the mimetics, while the ring structure 
probably interacts with a receptor surface next to 
that of the specific receptor for the mimetic. The 
conclusion is that the relationship in the chemical 
structure of mimetics and the corresponding lytics 
may become very slight. As has already been said, 
the chemical structure of the various lytics, cho-
linolytics, antihistaminics and sympatholytics have 
certain characteristics in common. This means that 
on the basis of this relationship in the chemical 
structure it may be expected that antihistaminics will 
possibly behave as cholinolytica and as sympatholytics 
too and vice versa. It is well known that many so-
called antihistaminics have cholinolytic as well as 
sympatholytic properties (5l)· 
The configuration of the ring structures is, how-
ever, not indifferent,as was demonstrated in a study of 
a number of dimethylaminoethylbenzhydryl ethers (52)· 
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Parasympatholytics Sympatholytics 
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/ o 
C-C-C-N 
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o 
C—C 
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C-O-C- C-N 
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C-C / ч / 
S N-C-C-N 
ν y ι ч 
С C-C 
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From these experiments it may be concluded that cer­
tain ring configurations are especially suitable 
to fit the receptors of antihistaminics, others for 
the receptors of cholinolytics. For configurations in 
which the characteristics of both are combined, anti-
histaminic and cholinolytic activity are represented 
more or less equally strongly. 
For most of the antihistaminics, cholinolytics and 
sympatholytics used in the clinic, one of the com­
ponents in the action dominates. This is because the 
compounds are selected for it. In the phenothiazine 
derivatives such as chlorpromazine an example has 
been found in which a combination of the various lyt­
ic properties in one compound appears to be useful 
for clinical purposes. 
The arguments just given make it possible to under­
stand that, as in the group of sympatholytic com­
pounds, the relationship in the structure between 
mimetics and lytics is often not very clear. 
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C h a p t e r 4 
S P A R E R E C E P T O R S . T H E O R E T I C -
A L C O N S I D E R A T I O N S . 
k.l I n t r o d u c t i o n . 
In the following pages the relationship between 
stimulus and effect will especially have our atten-
tion. As mentioned in chapter 2, paragraph 2.4.1, the 
effect of a drug was supposed to be linearly propor-
tional to the quantity of drug-receptor complex. This 
because the stimulus was supposed to be linearly pro-
portional to the quantity of drug-receptor complex, 
while in its turn the effect was supposed to be linear-
ly proportional to the stimulus. The proportionality-
constant between the drug-receptor complex and the 
stimulus, which is called the intrinsic activity 
(l, 2), represents the ability of the drug to contrib-
ute to the effect and varies with the drug concerned. 
The relation between stimulus and effect is indepen-
dent of the drug. A certain value of the stimulus al-
ways means a certain effect, independent of how the 
stimulus was induced or how much drug-receptor com-
plex had to be formed to obtain the stimulus. The 
maximal effect produced by a drug then requires the 
occupation of all receptors. 
Most people who have been working on receptor-drug 
interactions are aware of the fact that a linear re-
lationship between the amount of receptors occupied 
and the effect is far too simple. Recently Nickerson 
(3)1 Stephenson (4) and Ariens (5) on the grounds of 
experimental data have stressed the fact that the 
maximal response obtained with the biological object 
needs not be based on the occupation of all receptors. 
If the effect obtained by a drug is not linearly re-
lated to the quantity of drug-receptor complex form-
ed, one may suppose that the relation between the 
quantity of drug-receptor complex and the stimulus 
is still a linear proportionality, while the relation 
between stimulus and effect is non-linear. 
The proportionality-constant or the intrinsic activ-
ity, called efficacy by Stephenson, now in the first 
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instance concerns the ability of the drug to contrib­
ute to the stimulus (5)· 
For the relation between stimulus and effect var­
ious possibilities may be assumed, viz.: 
1. an all-or-none response, which means that the ef­
fector unit gives a response, a full response, if 
the stimulus reaches a certain value τ, the trig­
ger value or response value (5), 
2. the relation between stimulus and effect may be 
some non-linear but continuous function, e.g. a 
hyperbolic function (4) oran exponential one (6). 
This means that the contribution to the effect with 
a certain rise in the stimulus decreases with the in­
crease in the stimulus. Thus for high values of the 
stimulus or for high effects, a further increase in 
the stimulus hardly contributes any longer to the 
effect. This means that a practically full response 
may be obtained after only a fraction of the receptors 
is occupied by the drug. 
4.2 A l l - o r - n o n e r e s p o n s e . 
As a rule the isolated organs used are composed of 
many effector units, such as for muscular tissues, 
the various muscle cells or even the fibres. 
The response value, τ, for the different units may 
show a variation according to a certain frequency 
distribution (6). For a normal frequency distribution 
the log. concentration-effect curves will be practic­
ally covered by a dose range which correlates with a 
stimulus range from (τ+ 3σ) to ( τ - Ja), in which τ 
is the mean response value (6, 7)· 
The effect of the biological object as a whole loses 
its all-or-none character. A graded response is ob­
tained after a certain threshold value for the stim­
ulus, viz. ( τ - 3σ) bas been reached. 
The maximal value that may be reached for the stim­
ulus is determined by the intrinsic activity of the 
drug, consequently, the question whether τ will be 
reached for the various effector units is determined 
by the intrinsic activity of the drug used. Here as 
well as for the relationship discussed in chapter 2 
the character of the drug depends on the intrinsic 
activity. 
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A differentiation can be made between: 
a. a g o n i s t s . 
With a compound A with a value of the intrinsic 
activity α > (τ + 3σ) a full response of the organ 
may be obtained before all receptors are occupied by 
the drug. There is a reserve in receptors determin­
ed by α - ( Τ + 3σ) ; one might as well call it a re­
serve in the stimulus. On the other hand there is a 
threshold value for the stimulus (τ- Ja),below which 
practically no response is obtained. 
b . c o m p e t i t i v e a n t a g o n i s t s . 
With a compound A w i t h a v a l u e of a < ( τ - 3 σ ) , 
hardly any response is obtained. As these compounds, 
however, occupy the same receptors as those mention­
ed under a., they will behave as competitive antag­
onists of the agonists, 
с p a r t i a l a g o n i s t s . 
With a compound A with a value of α so that (τ -
Зет) < α < ( T+ 3σ) , it is impossible to reach an 
effect equal to the maximal effect obtained with the 
agonists mentioned above. The compound behaves as a 
partial agonist. 
If the maximal effect for the particular partial ag­
onist is reached, all receptors are occupied, which 
implies that there is no reserve in receptors. 
4.3 C o n t i n u o u s n o n - l i n e a r r e ­
l a t i o n s h i p b e t w e e n s t i m ­
u l u s a n d e f f e c t . 
As mentioned before in the case of certain contin­
uous non-linear functions between the stimulus and 
the effect, a practically full response may also be 
obtained after only a fraction of the receptors is 
occupied.Such a relationship may be based,for instance, 
on a feedback in the contraction process of the isol­
ated muscle. If the contraction is measured in an 
"isotonic" way after a certain shortening of the or­
gan, as a result of the development of internal ten­
sions,the contraction becomes more and more isometric-
al, which implied that as long as only the shortening 
of the muscle is measured as effect, after a certain 
shortening, the effectivity of the increase in the 
stimulus decreases. 
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While the receptor reserve in the case of an all-
or-none response might he called a real receptor re-
serve, this time the receptor reserve, based on the 
mechanical events in the contraction of the isolated 
organ or on the impossibility to determine the res-
ponse in a really isotonic way,may be called a virtual 
receptor reserve. 
4.4 T h e e x i s t e n c e o f s p a r e 
r e c e p t o r s . 
If there are spare receptors for a drug, it must 
be possible still to obtain a full response after a 
certain fraction of the receptors are blocked irre-
versibly. A fraction of the receptors equal to the 
reserve can be dispensed with.The irreversible block-
ade will show up the real as well as the virtual re-
serve in receptors. 
Log concentration-response curves made in the presence 
of an irreversibly blocking agent for the receptors 
concerned will manifest a practically parallel shift 
of the log concentration-response curves in the case 
of a receptor reserve. The loss in receptors may be 
compensated for by an increase in the concentration 
of the drug. The antagonism is surmountable to a cer-
tain degree. 
If the reserve in receptors is exhausted by the ir-
reversibly blocking agent, a further increase in the 
number of receptors blocked will result in a reduc-
tion of the curves of the type as seen in the case of 
a non-competitive antagonism (3)· 
The degree of shifting in the curves thus depends 
on the reserve in receptors and this in its turn on 
the intrinsic activity of the drugs. Drugs which may 
produce the maximal response possible for the bio-
logical object with the type of drug concerned, may 
vary in their intrinsic activity. 
The differences in intrinsic activity are reflected 
by differences in the reserve in receptors, thus a 
difference in intrinsic activity will result in a 
variation in the parallel shift in the curves by the 
irreversibly blocking agent.The greater the intrinsic 
activity, the greater the shift. 
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In the case of a receptor reserve, an irreversibly 
blocking agent causes a decline of the curves preced­
ed by a parallel shift, while the concentration range 
over which the shift takes place, is a measure for 
the receptor reserve. For partial agonists, the de­
crease in a number of specific receptors will result 
in a decline in the log concentration-response curves 
without a preceding shift (6). 
Musculotropic drugs are supposed to disable the 
muscle cells as far as the contraction is concerned, 
without interfering with the interaction of the spas-
mogen with its specific receptors or the evocation 
of the stimulus. In the case of the real receptor re­
serve, without an interference of the mechanical 
events, the musculotropic spasmolytics will induce a 
reduction of the log concentration-response curves 
without a preceding shift. 
If, however, a reserve in receptors is based on 
mechanical events as described before, the use of 
musculotropic spasmolytics will also result in a 
parallel shift in the log concentration-response 
curves, followed by a reduction in the curves. 
4.5 I r r e v e r s i b l e " c o m p e t i t i v e " 
a n t a g o n i s t s . 
The irreversible reaction of a drug В with the 
receptor R may be represented by the following equa­
tion: 
R + В — • BB 
The irreversible formation of RB and thus the ir­
reversible elimination of receptors depends on the 
concentration of the drug В and the time of incuba­
tion. The fraction of receptors left free, thus avail­
able for an agonistic or partial agonistic compound 
A, will be an exponential function of the time of 
incubation, t, the concentration of В and the reac­
tion velocity kj,. 
This implies that the stimulus 8дв/З
т
 evoked by an 
agonist A brought into contact with the receptor sys­
tem after incubation with an irreversible antagonist 
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В may be represented by the following formula (6): 
SAB/SD. "
 α
 *
 1 / ( 1 +
 V W » * êt^'b' 
The maximal stimulus to be obtained with A now becomes : 
SAB / S - α . ё М Ч 1 A B
m a x • 
The consequence for both agonist and partial agonist 
is that the stimulus is lowered. 
In the case of an agonist with a receptor reserve 
the inhibitive action of the irreversibly blocking 
agent is surmountable, because of the reserve in the 
stimulus. The maximal response for the agonist only 
drops when the receptor reserve is exhausted (fig. l). 
EAB/E
m
 „ . .. ΓΓΊ
 EAB/Em-
Theoretical log concentration-response curves for the agonist A 
(a = 1, K A = 1) (la) a n d a partial agonistA (a = 0.7, Кд = 1) (lb) 
reacting ina reversible way with a receptor system that has been 
for the time t in contact with an irreversible competitive antag­
onist В (k bt = 1 ) . 
The effect is assumed to be based on an all-or-none response, the 
response value, τ , which is distributed according to a normal 
frequency distribution (T = 0.5, and σ = 0 . 1 ) . 
Note the decline in the curves, which is preceded by a shift in 
the case of an agonist-
In the case of a partial agonist the inhibitive action 
of the irreversibly blocking agent is unsurmountable, 
because there is no reserve in the stimulus. 
There is no shift of the curve but only a decline of 
the height and the slope as the result of the irre­
versible drug. 
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C h a p t e r 5 
S P A R E R E C E P T O R S . E X P E R I M E N T S . 
5.1 I n t r o d u c t i o n . 
The aim of our thesis was the study of the gradual 
change from agonists to competitive antagonists in 
homologous series of sympathetic and parasympathetic 
drugs. Chapter 3 demonstrates the probability that 
this change is based on a gradual decrease in the 
intrinsic activity in such a way that in the trans-
ition of mimetics to lytics partial agonists are 
found. 
The following questions arise: 
I. Is there a reserve in receptors for, say, arter-
enol on the isolated vas deferens and MeFMe-r.a 
parasympathomimeticum,on the isolated gut of the 
rat? 
II. If such a reserve exists: Is the reserve for 
arterenol different from that of adrenaline and 
do their intrinsic activities differ? The same 
question obtains for MeFMe-r as compared with 
HFMe-j and EtFMe·}, also parasympathomimetics. 
III. If the receptor reserve for the agonist mention-
ed above exists: How do the partial agonists 
behave in this respect? 
5.2 I r r e v e r s i b l y b l o c k i n g 
a g e n t s . 
As mentioned, substances are known that are able 
to block irreversibly the specific receptors for the 
neurotransmitting substances. They belong to the 
group of the /Ö-halo-alkylamines and are related to 
the nitrogen mustards. 
The yd-halo-alkylamine dibenamine, used in these ex-
periments, has the following formula: 
o- N-C-C-Cl 
/ 
С 
The irreversible binding with the receptors proceeds 
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probably in the following way (l): 
CK _ O - s ^ ^ CK 
N-c-c-ci ri яч N + !z; 
O-c' CK N c о •с 
The carboniuin group of the ethylenimmonium inter­
mediate of dibenamine may perhaps react with a car-
boxylate or phosphate group of the receptor (2). 
Originally these compounds were described as sympath­
olytics (3) and it was shown to be probable that they 
block the specific receptors for e.g. arterenol (4). 
Furchgott (5) showed that these compounds not only 
block sympathetic receptors,but that also the specif­
ic receptors for histamine and even the parasympathe­
tic receptors are blocked irreversibly by dibenamine 
and its derivatives. 
Notwithstanding this non-specificity of the blockade, 
the action of dibenamine can be counteracted by var­
ious substances in a specific way. A high dose of 
a sympathomimetic or a reversibly acting sympatholytic 
can protect the sympathetic receptors against blockade 
by the/;-halo-alkylamines, but not the parasympathetic 
receptors nor the specific receptors for histamine. 
In other words there is no cross-protection between 
sympathetic parasympathetic or histaminic drugs (5)· 
The existence of spare receptors was shown as prob­
able by Nickerson (6), who was able to show that the 
log.concentration-response curve for histamine tested 
on the isolated guinea pig intestine is shifted along 
the log. concentration axis by the compound N-a naph-
tylmethyl N-ethyl-/? bromoethylamine, an irreversibly 
blocking antagonist of histamine. 
Analogous results were obtained by Furchgott (7) 
in experiments with adrenaline on the isolated rabbit 
aorta. He found that dibenamine caused a parallel 
shift, followed by a decline of the curves. 
5.З M e t h o d s a n d m a t e r i a l s . 
The experiments were carried out in the following 
way. The vas deferens and the intestine of the rat 
respectively were suspended in an organ bath as des­
cribed in chapter 3, section 3*2.5· As the action of 
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dibenamine is dependent on its concentration and the 
incubation time, inali experimente the blocking sub­
stance was left in contact with the biological object 
for 10 min. After washing thoroughly for 10 min., 
changing the bathfluid 2 or 3 times every 2 or 3 min­
utes, cumulative doses of the mimetics are given. In 
the protection experiments during the incubation time 
of the irreversibly blocking agent, a high dose of 
either a competitive sympatholytic or parasympathol­
ytic substance is present. 
5.4 P r o t e c t i o n a g a i n s t d i b e n ­
a m i n e b l o c k a d e . 
For the purpose of our experiments we had to find 
out if dibenamine blocks in an irreversible way the 
sympathetic receptors in the isolated vas deferens 
of the rat and the parasympathetic receptors in the 
isolated intestine of the rat. We did so by studying 
log concentration-response curves for arterenol on 
"/Ό contraction· 
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C u m u l a t i v e l o g c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r МеРМез as 
t e s t e d on t h e j e j u n u m o f t h e r a t a f t e r 10 m i n . I n c u b a t i o n w i t h 
v a r i o u s c o n c e n t r a t i o n s o f d i b e n a m i n e i n t h e p r e s e n c e a n d a b ­
s e n c e o f В и г Р М е ч . 
N o t e t h e s h i f t o f t h e c u r v e and t h e d e c r e a s e o f t h e m a x i m a l 
h e i g h t and t h e s l o p e a f t e r i n c u b a t i o n w i t h d i b e n a m i n e i n t h e 
a b s e n c e o f Bu2^Me-i· A f t e r i n c u b a t i o n w i t h d i b e n a m i n e i n t h e 
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p r o t e c t i o n o f t h e s p e c i f i c r e c e p t o r s . 
C u m u l a t i v e log c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r a r t e r e n o l as 
t e s t e d on t h e vas d e f e r e n s o f t h e r a t a f t e r 10 m i n . i n c u b a t i o n 
w i t h d i b e n a m i n e i n t h e p r e s e n c e and a b s e n c e o f Op i I on and 
a f t e r 10 m i n . i n c u b a t i o n w i t h a h i g h c o n c e n t r a t i o n o f O p i l o n . 
N o t e t h e s h i f t o f th e c u r v e a f t e r i n c u b a t i o n w i t h d i b e n a m i n e 
and t h e l e s s e r s h i f t a f t e r i n c u b a t i o n w i t h d i b e n a m i n e i n t h e 
p r e s e n c e o f O p i l o n , w h i c h i n d i c a t e s a p r o t e c t i o n o f t h e s p e c i f i c 
re сер t o r s . 
the isolated vas deferens after incubation with diben­
amine in the presence and in the absence of the sym­
patholytic drug opilon and by studying log concen­
tration-response curves for MeFMe-j, a parasympathomi­
metic, on the isolated jejunum of the rat after in­
cubation with dibenamine in the presence and the ab­
sence of the compound В^ГМет, a parasympatholytic. 
Opilon and ik^FMe·} are competitive antagonists for 
arterenol and MeFMe^ respectively, on the correspond­
ing isolated organs. See fig. 3-12a and 5-4b. The 
blocking action of dibenamine could be counteracted 
by these competitive antagonists as may be seen from 
fig. 5-lb and 5-la. So dibenamine is a suitable sub­
stance to demonstrate a possible receptor reserve for 
arterenol on the isolated vas deferens and for MeFMe·* 
on the isolated gut of the rat. 
5.5 S y m p a t h e t i c d r u g s . 
In the foregoing it has been seen that only those 
drugs that can give the maximal response with a bio­
logical object may possibly exhibit a receptor re­
serve. 
Arterenol and N-methylarterenol, which in fact pro­
duce maximal responses,may effect a receptor reserve. 
This indeed appeared to be the case, fig. 5-2a and 
5-2c.The previous incubation with dibenamine results 
in a decline of the maximal height and the slope of 
the curves which is preceded by a parallel shift. 
From fig. 5-2 it may be seen that the curves for 
arterenol are shifted over a larger dose-tract than 
those for N-methylarterenol. This indicates that the 
intrinsic activity of arterenol is greater than that 
of N-methylarterenol. Thus in these homologous series 
of arterenol derivatives the intrinsic activity grad­
ually drops while lengthening the alkyl chain on the 
nitrogen atom. 
N-ethylarterenol which does not give a maximal con­
traction (table 3-l) shows in the presence of diben­
amine a shift of the curves on which is superimposed 
a decline of the maximal height and the slope, see 
fig. 5-2b and compare with fig. 4-1. 
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N - E t a r t e r e n o I and N - M e a r t e r e n o I a f t e r 1 0 m i n . i n c u b a t i o n 
w i t h v a r i o u s c o n c e n t r â t ions o f d i b e n a m i n e as t e s t e d on t h e 
vas d e f e r e n s o f t h e r a t « 
N o t e t h e s h i f t and t h e dec I i ne o f t h e h e i g h t and t h e s l o p e 
o f t h e c u r v e s n h i c h i s p r e c e d e d by a s h i f t in the case o f 
a r t e r e n o l l a ) a n d N-Me a r t e r e no I I d . T h i s i n d i c a t e s a 
r e c e p t o r r e s e r v e f o r a r t e r e n o l and N - M e a r t e r e n o 1 . 
Fig. 5-3 gives an original registrogram of an experi-
ment with arterenol and N-ethylarterenol on the vas 
deferens of the rat. 
The pD2 values as calculated from the original log. 
concentration-response curves indicate that the af-
finity of N-methylarterenol is greater than those of 
arterenol and N-ethylarterenol (see table 3-l)· 
Consequently there may be a maximum in the affinity. 
The experiments with the irreversibly blocking agent 
dibenamine explicitly suggest the probability that N-
methylarterenol had in fact the higher affinity. 
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Fig- 5-3 Original reg istrogram of the action of cumulative d o s e s of a r t e -
renol and N - E t a r t e r e n o I a f t e r 10 m i n . i n c u b a t i o n w i t h v a r i o u s 
c o n c e n t r a t i o n s of d i b e n a m i n e f o l l o w e d by 10 m i n . rinsing bath. 
The exact values of the intrinsic activity and af­
finity cannot be calculated from these experiments, 
since there is a rather large variability in the ex­
perimental results. A procedure for evaluating those 
parameters with the aid of irreversibly blocking 
agents has been evolved earlier (8). 
5.6 P a r a s y m p a t h e t i c d r u g s . 
For the study of the receptor reserve for para­
sympathetic drugs a number of compounds from a homol­
ogous series of dilvasène was chosen, with one hydr-
ogen atom replaced by an alkyl group increasing in 
length (see table 5-1)· It has been shown by van Ros-
sum (β) that lengthening the alkyl chain in this 
series results in a gradual decrease of the intrinsic 
activity. The lower members of the series, HFMe^j, 
MeFMe^ and EtFlie? appeared to have equal intrinsic 
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activities, while the propyl derivative is a partial 
agonist, see fig. З-^а (β). 
Table 5-1 Intrinsic a c t i v i t i e s and a f f i n i t i e s (expressed as ρ D2 ami рАг 
values) of d ï l v a s ï n e tested on the rat jejunum ( 8 ) . 
о — С
 r 
„ X C-C-N+-C 
О С 
Η (dilvasêne) 
Me 
Et 
Pr 
Bu 
Hex. 
i. a. 
α β 
1 
1 
1 
0.5 
0 
0 
PD, 
5.3 
7.2 
5.4 
4.9 
рА, 
4.9 
4.5 
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s e r i e s o f d i l v a s ê n e c o m p o u n d s . N o t e a p r o g r e s s i v e d e c l i n e o f 
t h e h e i g h t and t h e s l o p e o f t h e c u r v e s » i t h e l o n g a t i o n o f the 
a l k y l c h a i n R ' , w h i c h i n d i c a t e s a p r o g r e s s i v e d e c r e a s e o f the 
i n t r i n s i c a c t i v i t y , 
b. C u m u l a t i v e log c o n c e n t r a t i o n - r e s p o n s e c u r v e s f o r HFMe^ in the 
p r e s e n c e o f c o n s t a n t c o n c e n t r a t i o n s o f В и г ^ М е з · N o t e t h e p a r ­
a l l e l s h i f t o f t h e c u r v e s f o r t h e a g o n i s t w h i c h i n d i c a t e s a 
c o m p e t i t i v e a n t a g o n i s m . 
It may be expected that dibenamine will cause a de­
crease of the maximal height of the curves for РгГМез 
without a preceding shift since a receptor reserve 
cannot exist, PrFMej is a partial agonist, it was 
possible to confirm this expectation experimentally. 
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EtFMe·*, which has only just an intrinsic activity 1, 
may have, if any, a very small receptor reserve. From 
concentration-action curves as presented in fig. 5-
3c, it may he seen that dibenamine causes only a de­
cline in the curves for EtFiie-z, which indicates a 
lack of spare receptors for this compound. 
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Fig. 5-5,a-b-c Cumulative log con cen t га t Ϊ o n - respon se curves for MFMe·^, 
МеРМез and EtFMe-j after incubation with dibenamine during 
various times as tested on the jejunum of the rat. 
Note the shift and the decline of the height and the slope 
of the curves which is preceded by a shift in the case of 
HFMej (a) and MeFMej (b). This indicates a receptor reserve 
for HFMe3 and МеРМеЗ-
which are agonists, actually 
have a receptor reserve, see fig. 5-5a and b. 
HFMe^ and ìieFìie-^, 
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For both compounds dibenamine causes a shift of the 
curves and eventually the receptor reservéis exhaust-
ed,which results in a decrease in the maximal height. 
The amount of shifting is practically identical for 
both these drugs, which implies equal intrinsic act-
ivities. 
So there is indeed a gradual decrease of intrinsic 
activity with increasing length of the alkyl chain 
in the series of dioxolane derivatives studied. 
As may be seen from table 5-1 and fig. 5-^, there 
is a maximum in the pD2 values for the MeFMe-j compound 
in this series. Before irreversibly blocking antag-
onists became available,it was not possible to decide 
whether this optimum should be ascribed to the af-
finity. 
The maximum in the pD2 value of MeFMe^ might as well 
be attributed to an optimum in the intrinsic act-
ivity. From the experiments presented before with 
dibenamine it can be concluded that the difference in 
the pD2 values for IIFMe-j and MeFMe-j as given in table 
5-1 may be ascribed to a difference in the affinity 
of MeFMe-r. Consequently in the RFMe^ series there is 
an optimum in the affinity for MeFMe-τ, which implies 
that the 5-atom rule of Ing (9) holds for the af­
finity. 
5.7 T h e v i r t u a l r e c e p t o r r e ­
s e r v e . 
In the case of papaverine,a musculotropiс spasmo­
lytic, which behaves as a non-competitive antagonist 
of various spasmogens, the decline of the height and 
the slope of the curves for the spasmogen is some­
times preceded by a shift of the curves. 
This phenomenon especially appears with the intestine 
of the guinea pig, an organ with much connective tiss­
ue and various layers of smooth muscle fibres. 
A possible explanation for the shift of the curves 
is the existence of a virtual receptor reserve as 
described in chapter k, paragraph 4.4, so on the basis 
of mechanical events. 
The phenomenon of a receptor reserve based on me­
chanical events plays a part, too, if dibenamine is 
used as an antagonist of a spasmogen on the jejunum 
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of the guinea pig. Only a part of the shift of the 
curve for the spasmogen brought about by dibenamine 
or its derivatives may be ascribed to the "real" re-
ceptor reserve, a part of the shift must be ascribed 
to the virtual receptor reserve. 
A fraction of the large amount of spare receptors 
(99/0 found by Nickerson (6) with experiments on the 
guinea pig using histamine as a spasmogen and N-a 
naphtylmethyl N-ethyl-p bromoethylamine as an irre-
versibly blocking agent, may be ascribed to a virtual 
receptor reserve. 
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S U M M A R Y . 
The purpose of this research was to ascertain how 
the transition from mimetics to lytics takes place in 
a series of derivatives of neurotransmitters. Neuro-
transmitters are substances that bring about the 
transmission of nerve impulses between the various 
nerve cells, neurons, and between a nerve cell and a 
cell of the effector organ. 
In the introduction an examination was made of the 
literature of the subject as to what substances may 
act as neurotransmitters. 
After an historical survey of the discovery, the 
pharmacology and the biochemistry of a number of 
transmitters in Chapter 1, we have in Chapter 2 de-
voted some observations to the action of drugs based 
on the receptor theory. Here stress is especially laid 
upon the fact that, in studying the relationship be-
tween the chemical structure and the biological ac-
tion in series of substances, a distinction must be 
made between affinity and intrinsic activity. Only 
concentration-action curves offer a useful experimen-
tal starting-point for such a study. Such curves are 
obtained most easily by the aid of isolated organs. 
In Chapter 3 the relationship has been traced be-
tween the structure and action in series of derivat-
ives of arterenol and acetylcholine with the help of 
cumulative concentration-action curves of these sub-
stances. The series of derivatives mentioned were 
especially chosen for the research because of arter-
enol and acetylcholine lytics, competitive antag-
onists are known, which strongly resemble in struc-
ture the respective mimetics. This was taken as an 
indication that substances exist that form a transi-
tion between mimetics and lytics. This expectation 
was confirmed by the experiments. In the series of 
arterenol derivatives studied, as well as in that of 
the acetylcholine derivatives, a gradual transition 
takes place from mimetics to lytics, from agonists to 
competitive antagonists via substances possessing 
both a mimetic and a lytic action. These substances, 
therefore,show a dualism in action and are also call-
ed partial agonists. 
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Besides a series of arterenol derivatives,a series 
of sympatol derivatives was also examined. Here, 
too, a gradual transition from mimetics to lytics via 
dualistically active substances was observed. 
Arterenol and sympatol are chemically closely re-
lated sympathomimetics possessing a distinct diffe-
rence in affinity to the receptors. Ilowever, when 
lytics are obtained from the substances by aralkyl 
substitution on the N-atom, it appears that these 
have a good, but mutually equal, affinity to the re-
ceptors. This is explained by assuming that the lyt-
ics, especially in the phenyl group in the aralkyl 
substituent, interact with a more extensive receptor 
area than the corresponding mimetics, arterenol and 
sympatol. 
Where the substituted part of the molecules is 
concerned, there is, therefore, no difference in af-
finity to the receptors between the arterenol and sym-
patol derivatives.This makes the difference in affi-
nity between the respective lytics smaller than the 
difference in affinity between the mimetics. With the 
aid of the same hypothesis the decrease in the spec-
ificity of different lytics, as compared with that 
of the mimetics, can be explained. This accounts, for 
instance, for the fact that various anti-histaminics 
also possess, beside their anti-histamine action, 
parasympatholytic and sympatholytic qualities. 
In the series of N-substituted arterenol and sym-
patol derivatives (table 3-1 and 3-2) substances oc-
cur in the transition from mimetics to lytics with a 
very low affinity to the specific arterenol receptors. 
For this reason a a-specific papaverine-like action 
may dominate in these substances, causing an apparent 
discontinuity in the transition f rom mimetic to lytic. 
Especially in the arterenol and sympatol derivatives 
with a strong structural resemblance to papaverine is 
this a-specific spasmolytic action in evidence. This 
phenomenon was not observed in the series of acetyl-
choline derivatives studied. In this case, however, 
we have quaternary ammonium combinations,which makes 
a papaverine-like action very improbable. 
As a test object for the arterenol derivatives the 
isolated vas deferens of the rat was used, and for 
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the acetylcholine derivatives the isolated jejunum of 
the rat. 
In Chapter 4 the theoretical considerations are 
extended further. The supposition in Chapter '2 that 
there is a linear relation between the number of oc-
cupied receptors and the effect is, as a matter of 
fact, not quite correct. In this respect the occur-
rence of a reserve of receptors is dealt with, that 
is to say that a maximal effect can be obtained with 
a drug without all the specific receptors being oc-
cupied by the drug in question. 
In order to demonstrate a reserve of receptors irre-
versibly blocking substances are required. 
In Chapter 5 experiments are described, for the 
purpose of demonstrating a possible receptor reserve. 
Here dibenamine is used as an irreversibly blocking 
substance. Both in the case of arterenol and adrena-
line as regards the isolated vas deferens and in the 
case of a number of di-oxolan derivatives as regards 
the isolated jejunum of the rat the occurrence of a 
receptor reserve is made probable. The fact is point-
ed out that experiments witha non-competitive antag-
onist of various spasmogenes on the isolated gut of 
the guinea pig indicate that possibly a part of the 
receptor reserve just mentioned is not real but must 
be ascribed to the mechanical processes interfering 
with the isotonic contraction of the organs studied. 
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S A M E N V A T T I N G . 
Uet doel van het onderzoek was na te gaan hoe in 
reeksen derivaten van neurotransmitters de overgang 
van mimetica naar lytica plaats vindt. Neurotrans-
mitters zijn stoffen, die zorgen voor de overbrenging 
van zenuwimpulsen tussen de verschillende zenuwcellen, 
neuronen, en tussen een zenuwcel en een cel van het 
effectororgaan. 
In de inleiding wordt aan de hand van de litera-
tuur nagegaan, welke stoffen een rol kunnen spelen 
als neurotransmitter. 
Na een historisch overzicht van de ontdekking, de 
farmacologie en de biochemie van een aantal neuro-
transmitters, hoofdstuk 1, worden in hoofdstuk 2 eni-
ge beschouwingen gewijd aan de werking van farmaca 
op basis van de receptor theorie. Hierbij wordt voor-
al de nadruk gelegd op het feit, dat, wil men de re-
latie tussen de chemische structuur en de biologische 
werking in reeksen van stoffen bestuderen, een onder-
scheid moet worden gemaakt tussen affiniteit en in-
trinsieke activiteit. Alleen concentratie-werkings-
curven leveren een bruikbaar experimenteel uitgangs-
punt voor een dergelijke studie. Zulke curven worden 
het eenvoudigst verkregen met behulp van geïsoleerde 
organen. 
In hoofdstuk 3 wordt het verband tussen de struc-
tuur en de werking nagegaan in reeksen derivaten van 
arterenol en acetylcholine aan de hand van cumulatieve 
concentratie-werkingscurven van deze stoffen. Spe-
ciaal de genoemde reeksen derivaten werden voor het 
onderzoek gekozen, omdat van arterenol en acetylcho-
line lytica, competitieve antagonisten, bekend zijn, 
die een sterke overeenkomst in structuur bezitten met 
de respectievelijke mimetica* Hierin werd een aan-
wijzing gezien voor het bestaan van stoffen, die een 
overgang vormen tiTssen de mimetica en de lytica. Deze 
verwachting werd door de experimenten bevestigd. Zo-
wel in de reeks van de door ons bestudeerde arterenol 
derivaten, als in die van de acetylcholine derivaten 
heeft een geleidelijke overgang plaats van mimetica 
naar lytica, van agonieten naar competitieve antago-
nisten, via stoffen die zowel een mimetische als een 
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lytische werking bezitten. Deze stoffen vertonen dus 
een dualisme in de werking en worden ook wel partiële 
agonisten genoemd. 
Naast een reeks arterenol derivaten werd eveneens 
een reeks sympatol derivaten onderzocht. Ook hier 
wordt een geleidelijke overgang van mimetica naar 
lytica via dualistisch werkende stoffen waargenomen. 
Arterenol en sympatol zijn chemisch nauw verwante 
sympathomimetica, die een duidelijk verschil in af-
finiteit voor de receptoren bezitten. 
Wanneer echter uit deze stoffen door aralkyl substi-
tutie aan het N-atoom lytica worden verkregen, blijkt, 
dat deze een goede, doch onderling gelijke affiniteit 
voor de receptoren bezitten.Dit wordt verklaard door 
aan te nemen, dat de lytica vooral door de fenylgroep 
in de aralkyl substituent met een uitgebreider re-
ceptorgebied in interactie treden dan de overeenkom-
stige mimetica, arterenol en sympatol. 
Waar het betreft het gesubstitueerde gedeelte van 
de moleculen, bestaat er dus geen verschil in affi-
niteit tot de receptoren tussen de arterenol en sym-
patol derivaten. Daardoor wordt het verschil in af-
finiteit tussen de respectievelijke lytica kleiner 
dan het verschil in affiniteit tussen de mimetica. 
Uet behulp van dezelfde hypothese kan de vermindering 
in de specificiteit van verschillende lytica in verge-
lijking met die van de mimetica worden verklaard. Zo 
b.v. het feit, dat verschillende anti-histaminica 
naast hun anti-histamine werking, ook parasympatho-
lytische en sympatholytische eigenschappen hebben. 
In de reeks van N-gesubstitueerde arterenol en 
sympatol derivaten (tabel 3-1 en 3-2) komen er bij 
de overgang van mimetica naar lytica stoffen voor met 
een zeer lage affiniteit voor de specifieke arterenol 
receptoren. Hierdoor kan bij deze stoffen de a-speci-
fieke papaverine-achtige werking domineren, waardoor 
er ogenschijnlijk een discontinuïteit optreedt bij de 
overgang van mimeticum naar lyticum. 
In het bijzonder bij de arterenol en sympatol deri-
vaten met een sterke structurele overeenkomst met 
papaverine is deze a-specifieke spasmolytische werking 
duidelijk aanwezig. Dit verschijnsel werd niet waar-
genomen in de door ons bestudeerde reeks van acetyl-
choline derivaten. 
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Wij hebben daarbij echter te doen met quaternaire 
ammonivun-verbindingen, waardoor een papaverine-achti-
ge werking zeer onwaarschijnlijk wordt. 
Als testobject werd voor de arterenol derivaten 
het geïsoleerde vas deferens van de rat, voor de ace-
tylcholine derivaten het geïsoleerde jejunum van de 
rat gebruikt. 
In hoofdstuk 4 worden de theoretische beschouwin-
gen uitgebreid. De aanname in hoofdstuk 2, dat er een 
lineair verband bestaat tussen het aantal bezette re-
ceptoren en het effect is nl. niet volledig juist. 
Hiertoe wordt behandeld het optreden van een reserve 
aan receptoren, hetgeen wil zeggen, dat met een far-
macon een maximaal effect verkregen kan worden zonder 
dat alle specifieke receptoren met het betrokken far-
macon bezet zijn. Om een reserve aan receptoren te 
kunnen aantonen zijn irreversibel blokkerende stof-
fen nodig. 
In hoofdstuk 5 worden experimenten beschreven, ge-
richt op het aantonen van een eventuele receptor re-
serve.Als irreversibel blokkerende stof wordt daarbij 
het dibenamine gebruikt.Zowel voor arterenol en adre-
naline voor wat betreft het geïsoleerde vas deferens 
als voor een aantal di-oxolaan derivaten voor wat 
betreft het geïsoleerde jejunum van de rat, wordt het 
voorkomen van een receptor reserve waarschijnlijk ge-
maakt. Er wordt gewezen op het feit, dat experimenten 
met een non-competitieve antagonist van verschillende 
spasmogenen aan de geïsoleerde darm van de cavia er 
op duiden, dat wellicht een deel van de hiervoor ge-
noemde receptor reserve niet reëel is, maar moet 
worden toegeschreven aan de mechanische processen, 
welke interfereren met de isotonische contractie van 
de bestudeerde organen. 
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